Introduction {#s1}
============

Psoriasis is a chronic auto-immune skin disease that affects 2--3% of the European population. Disease characteristics include epidermal hyperplasia, infiltration of leukocytes in the dermis and erythema ([@bib11]). Long-term activation of the immune system in the skin can also lead to tissue damage in other organs, and psoriasis is generally regarded as a systemic disease. Consequently, numerous comorbidities, including psoriatic arthritis, inflammatory bowel disease (IBD) and cardiovascular disease, are associated with psoriasis ([@bib21]).

Genome-wide association studies have revealed over 60 loci that contribute to the development of psoriasis. These include candidate genes involved in skin barrier function and the immune response ([@bib35]). It is thought that many low risk genetic variants together with environmental factors increase the predisposition of individuals to psoriasis development. Psoriasis vulgaris (PV), the most common form, is characterised by stable erythematous scaly plaques, predominantly located on knees and elbows, in which the adaptive immune system predominates. In contrast, generalised pustular psoriasis (GPP), a very rare form of the disease that is characterised by widespread diffuse skin inflammation and sub-corneal pustules (Munro's microabscesses and spongiform pustules of Kogoj), involves massive infiltration of neutrophils in the skin. GPP patients also experience acute exacerbations (flare ups) involving development of new skin lesions which can cover \>70% of the body surface, fever, cheilitis (scaling and superficial ulceration of the lips), diarrhoea and dehydration ([@bib40]). GPP exacerbations, which often meet the criteria for systemic inflammatory response syndrome, involve neutrophil infiltration in multiple organs, are difficult to treat and associated with significant morbidity and mortality (3--7%) ([@bib19]).

Gain-of-function, highly penetrant (\>90%) and dominantly acting mutations within the *CARD14* gene can trigger the development of PV or GPP ([@bib30]). CARD14 (CARMA2) is a member of the CARMA family of scaffolding proteins that includes CARD11 (CARMA1) and CARD10 (CARMA3) ([@bib39]). Each of these proteins has a similar domain structure, comprising an N-terminal CARD domain, followed by a coiled-coil (CC) domain, and a C-terminal MAGUK domain (PDZ-SH3-GUK). CARD11 and CARD10 play critical roles in the activation of NF-κB transcription factors following ligation of antigen receptors and G-protein-coupled receptors, respectively ([@bib39]). NF-κB, composed of dimers of Rel polypeptides, regulates gene expression by binding to κB elements in the promoters and enhancers of multiple target genes that control immune and inflammatory responses ([@bib60]).

The structural similarity to CARD11 and CARD10 suggests a role for CARD14 in NF-κB activation. Consistent with this, the highly penetrant *CARD14*^E138A^ psoriasis-associated mutation, first identified as a sporadic mutation in a child suffering from GPP ([@bib30]), induces CARD14 interaction with BCL10 (B cell lymphoma protein 10) and the paracaspase MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) ([@bib26]). This complex triggers activation of the IκB kinase (IKK) complex, the central activator of NF-κB transcription factors, leading to constitutive activation of NF-κB and expression of pro-inflammatory cytokine/chemokine genes in keratinocytes in the absence of exogenous stimulation.

Recent studies have investigated how psoriasis-associated *CARD14* mutations induce skin inflammation by generating knock-in mice expressing the mouse equivalent CARD14 variants ([@bib41]; [@bib52]; [@bib59]). These mice develop psoriasiform skin inflammation that is partially dependent on the cytokines IL-17A and IL-23, which play important roles in human psoriasis ([@bib21]). Although these studies have confirmed the importance of CARD14 mutations in inducing skin inflammation, the constitutive nature of the knock-in mutations generated have precluded detailed study of disease pathogenesis. Furthermore, the constitutive *CARD14*^E138A^ mutation is associated with embryonic or peri-natal lethality, preventing analysis of disease in adult skin. To circumvent these limitations, we generated a new knock-in mouse allele *Card14*^LSL-E138A^ that allows conditional expression of the human *CARD14*^E138A^ mutation in the homologous mouse locus following tamoxifen injection. The inducible nature of this mutation allowed us to study the direct effects of CARD14^E138A^ signalling, rather than potentially indirect secondary or tertiary consequences of constitutively expressed CARD14^E138A^. Tamoxifen-induced expression of *Card14*^E138A^ in adult mice also ruled out any developmental effects of CARD14^E138A^ signalling on skin inflammation.

We present evidence that conditional heterozygous expression of CARD14^E138A^ in adult mice rapidly promoted psoriasiform skin inflammation, which was independent of adaptive immune cells and due to signalling in keratinocytes. However, homozygous expression of CARD14^E138A^ induced rapid weight loss, temperature reduction and extensive neutrophil infiltration in multiple organs. This severe systemic phenotype resulted from CARD14^E138A^ signalling in keratinocytes and showed striking similarities to an acute flare of GPP in human patients. Heterozygous and homozygous phenotypes were both ameliorated by antibody neutralisation of tumour necrosis factor (TNF). Our findings suggest that specific blockade of the CARD14 signalling pathway in keratinocytes would inhibit the systemic inflammatory syndrome that can develop in GPP patients with activating CARD14 mutations.

Results {#s2}
=======

Human and mouse CARD14 proteins are highly homologous, with 77% amino acid identity overall and 80% identity in the coiled-coil region in which the *CARD14*^E138A^ mutation is located ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). To study how CARD14^E138A^ mutation induces skin inflammation, we developed a conditional knock-in mouse strain, *Card14^LSL-E138A/LSL-E138A^*, in which a floxed minigene (exons 4--22) encoding wild type (WT) C-terminus of CARD14 linked to a 3xFLAG tag was inserted between exons 3 and 4 of the *Card14* locus and an E138A point mutation was introduced into endogenous *Card14* exon 5 ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). In the absence of Cre-mediated recombination, *Card14* was expressed from exon 3 and the inserted minigene to produce WT CARD14-3xFLAG. After Cre-mediated recombination, the minigene was excised, allowing transcription of *Card14* from the endogenous exons and expression of CARD14^E138A^.

CARD14 is expressed at high levels in differentiated keratinocytes of the skin epidermis {#s2-1}
----------------------------------------------------------------------------------------

In order to understand the effects of *Card14*^E138A^ mutation, it was first important to know where CARD14 protein is normally expressed. High levels of CARD14-3XFLAG were detected in the back skin and ears, as expected, and also in the colon, small intestine and caecum ([Figure 1A](#fig1){ref-type="fig"}). Low levels of CARD14-3XFLAG were additionally found in the liver and kidney.

![Conditional expression of CARD14^E138A^ in *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice induces rapid changes in ear skin histology.\
(**A**) CARD14-FLAG protein expression analysed in total extracts from different organs from control (WT) and *Card14*^E138A-LSL^ (KI) mice by immunoblotting. (**B**) Localisation of *Card14* mRNA expression in the skin assessed by RNAscope. (**C**) Timeline of the *Card14*^E138A^ induction by tamoxifen and sample collection. (**D**) Representative histology images of ears on d5 after tamoxifen injection: (first panel) H and E staining and acanthosis quantification over time; (second panel) Ki67 staining at d5 and quantitation; (third panel) S100A9 staining at d5 and quantitation; (fourth panel) involucrin staining at d5 and (bottom panel) endomucin staining at d5. (**E**) qRT-PCR analysis of the expression of *IL17a, Tnfa*, *S100a9, Il17c* and *Il1f9* mRNAs. (**F**) Quantification and characterisation of the immune cell infiltrate of the ears at d5 after tamoxifen by FACS. Data pooled from 4 independent experiments; *Card14*^+/+^ *Rosa26*^CreERT2/+^n = 22, *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ 5d n = 22. Data collected from a mixture of male and female mice. (**B, D**) Scale bar = 100 µm. Differences between groups analysed by one-way ANOVA (D and E) or Student's t-test (**F**). \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001; \*\*\*\*, p\<0.0001. For clarity, only statistical analyses between the two genotypes at day 4 and day 5 were noted.](elife-56720-fig1){#fig1}

RNAscope analysis revealed that *Card14* mRNA expression in healthy mouse skin was restricted to the upper (most differentiated) keratinocytes, the outer root sheath of the hair and sebocytes in the skin ([Figure 1B](#fig1){ref-type="fig"}). These data contrasted with earlier immunohistochemistry results suggesting CARD14 expression in the basal layer of human skin ([@bib16]; [@bib30]). However, the RNAscope analyses were in line with published RNA sequencing data from different layers of the mouse epidermis ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) and single cell sequencing of murine epidermis (<http://kasperlab.org/mouseskin>) which also indicated *Card14* mRNA expression in differentiated keratinocytes ([@bib1]). Consistent with this, CARD14 protein expression was induced in mouse keratinocytes following in vitro differentiation in culture medium containing CaCl~2~ ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}; [@bib4]). *CARD14* mRNA and CARD14 protein expression was similarly induced in cultured human keratinocytes concurrent with the keratinocyte differentiation marker involucrin ([Figure 1---figure supplement 1E and F](#fig1s1){ref-type="fig"}). The *CARD14* mRNA expression data agree with published transcriptomic datasets of differentiating human keratinocytes ([@bib5]) and organotypic epidermis ([@bib37]; [Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}).

Heterozygous expression of CARD14^E138A^ rapidly induces psoriasiform skin inflammation {#s2-2}
---------------------------------------------------------------------------------------

Psoriasis-associated *CARD14* mutations in humans are generally heterozygous ([@bib29]). *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ mice were generated to test the effect of ubiquitous heterozygous expression of *Card14*^E138A^ following tamoxifen-induced minigene deletion ([@bib46]), according to the scheme in [Figure 1C](#fig1){ref-type="fig"}.

A time course experiment revealed that intraperitoneal tamoxifen promoted epidermal thickening (acanthosis), hyperkeratosis and keratinocyte proliferation (as indicated by Ki67 staining) in the ears 4--5 days (d) after the first injection ([Figure 1D](#fig1){ref-type="fig"}). Staining for the Ca^2+^-binding protein S100A9 showed CARD14^E138A^ increased infiltration of S100A9^+^ myeloid cells and also enhanced S100A9 expression in keratinocytes, which express S100A9 only following cell stress ([@bib14]). CARD14^E138A^ induced a broader distribution of the keratinocyte differentiation marker involucrin in the epidermis, indicative of altered keratinocyte differentiation. Increased staining for endomucin, an endothelial marker, showed that CARD14^E138A^ promoted neoangiogenesis. All these changes were also detected in the back skin of the mice following tamoxifen induction ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). In addition, mRNA expression of the psoriasis-associated genes *Il17a, Tnfa, S100a9, Il17c* and *Il1f9* was induced by tamoxifen in the ears and the back skin ([Figure 1E](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}).

Flow cytometry further characterised immune cells in the ears five days (5d) after tamoxifen injection (for gating strategy see [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). There was an extensive infiltration of immune cells in the ears of the *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ mice compared to *Card14*^+/+^*Rosa26*^CreERT2^ controls. Neutrophils, macrophages, dendritic cells (DC), CD4^+^ T cells, CD8^+^ T cells, regulatory T cells (Tregs), γδ T cells and NK cells were all found in significantly increased numbers 5d after tamoxifen injection ([Figure 1F](#fig1){ref-type="fig"}).

Together these results indicated that expression of CARD14^E138A^ promoted the rapid development of skin inflammation that shared many features in common with psoriasis ([@bib21]).

CARD14^E138A^ signalling in keratinocytes induces skin inflammation independently of the adaptive immune system {#s2-3}
---------------------------------------------------------------------------------------------------------------

CARD14 is expressed at high levels in skin keratinocytes but is also expressed at lower levels in intestinal epithelial cells and other tissues ([Figure 1A](#fig1){ref-type="fig"}). To test whether the skin inflammation in the *Card14*^LSL-E138A/+^Rosa26^CreERT2/*+*^ mice was caused by keratinocyte-intrinsic CARD14^E138A^ signalling, *Card14*^LSL-E138A/LSL-E138A^ mice were crossed with *Krt14*^CreERT2^ mice. Tamoxifen injection of the resulting *Card14*^E138A/+^ Krt14^CreERT2/+^ mice induced expression of CARD14^E138A^ in keratinocytes ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). This induced acanthosis, hyperkeratosis, infiltration of S100A9^+^ myeloid cells and increased expression of chemokines and proinflammatory cytokines in the ears and the back skin at 5d after tamoxifen injection ([Figure 2A,B,C,D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1B,C,D and E](#fig2s1){ref-type="fig"}). Some *Card14*^E138A/+^ *Krt14*^CreERT2/+^ mice presented a visible skin phenotype without tamoxifen injection, which could be due to leaky expression of Cre allowing basal expression of CARD14^E138A^, these were excluded from experiments. Skin expression of psoriasis-associated genes at 5d was increased in *Card14*^LSL-E138A/+^*Krt14*^CreERT2/+^ mice compared to controls, similar to *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). However, the fold changes for the majority of these transcripts were higher on the *Rosa26*^CreERT2^ background. Nevertheless, these experiments showed that CARD14^E138A^ signalling in keratinocytes alone was sufficient to induce skin inflammation.

![CARD14^E138A^ signalling in keratinocytes induces ear skin inflammation independently of the adaptive immune system.\
Eight-week old Card14^+/+^ *Krt14*^CreERT2/+^, *Card14*^LSL-E138A/+^ *Krt14*^CreERT2/+^, *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ *Rag1*^+/+^*, Card14*^+/+^ *Rosa26*^CreERT2/+^ *Rag1*^+/+^ and *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ *Rag1*^-/-^ mice were injected intraperitoneally with tamoxifen on days 0, 1 and 2. Mice were sacrificed and tissues analysed at 5d after the first injection of tamoxifen. (**A and E**) Immunohistochemistry of the ear stained for S100A9 at d5. (**B and F**) Quantification of acanthosis (**C and G**) Quantification of dermal immune cell infiltration. (**D and H**) qRT-PCR analysis of mRNA expression of the indicated genes in the ear. Fold changes in (H) were calculated by comparison with the *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ *Rag1^+/+^* group. (**A and E**) Scale bar = 100 µm. Data in B and C from 1 of 2 similar experiments with n ≥ 4, data in **D, F, G** and **H** pooled from 2 independent experiments with n ≥ 4 (**D**) and with n ≥ 6 (**F, G and H**). Differences between groups analysed by Student's t test (**B, C and D**) or one-way ANOVA (**F, G and H**). \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001; \*\*\*\*, p\<0.0001.](elife-56720-fig2){#fig2}

To investigate the role of the adaptive immune system in the development of CARD14^E138A^-induced skin pathology, *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^*Rag1*^-/-^ mice were generated that lacked T and B cells. Tamoxifen induced a skin phenotype very similar to *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ *Rag1^+/+^* controls, with acanthosis, hyperkeratosis, S100A9^+^ myeloid cell infiltration and expression of chemokines and proinflammatory cytokines at 5d following tamoxifen injection ([Figure 2E,F,G,H](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1F,G,H and I](#fig2s1){ref-type="fig"}). Consequently, the adaptive immune system was not required for acute skin inflammation induced by ubiquitous CARD14^E138A^ expression.

Neutralisation of TNF efficiently blocks skin inflammation induced by CARD14^E138A^ {#s2-4}
-----------------------------------------------------------------------------------

Two of the most common and efficient treatments for moderate to severe psoriatic patients are antibody blocking of TNF and IL-17A ([@bib21]). We next assessed whether the inflammatory skin phenotype induced by CARD14^E138A^ could be ameliorated by neutralising either of these cytokines following the protocol shown in [Figure 3A](#fig3){ref-type="fig"}.

![CARD14^E138A^-induced ear skin inflammation is ameliorated by anti-TNF.\
Eight-week old *Card14*^LSL-E138A/+^*Rosa26*^CreRT2/+^ and *Card14*^+/+^ *Rosa26*^CreERT2/+^ mice treated with either tamoxifen and blocking antibodies or with tamoxifen and isotype control IgG following the scheme in **A**. (**B**) Representative histological image of ear stained by H and E on d5 and acanthosis quantification from mice receiving the different treatments. (**C**) qRT-PCR analysis of the expression of indicated genes Fold changes were calculated by comparing with the *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ isotype treated group. (**D**) Quantification and characterisation of the immune cell infiltrate of the ears at d5 after tamoxifen by FACS. Data from 1 experiment (**B**) Scale bar = 100 µm. Data pooled from 2 experiments with at least n ≥ 4. Differences between groups analysed by one-way ANOVA. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001; \*\*\*\*, p\<0.0001. For clarity, only statistically significant differences have been noted in the graphs.](elife-56720-fig3){#fig3}

Anti-TNF substantially reduced acanthosis in ears and back skin of tamoxifen-induced *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice such that epidermal thickness was similar to that detected in *Card14*^+/+^ *Rosa26*^CreERT2/+^ control mice after tamoxifen injection ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Skin expression of mRNAs encoding chemokines and proinflammatory cytokines was also significantly reduced by anti-TNF in the ears and the back skin ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Flow cytometric analyses demonstrated that anti-TNF reduced infiltration of neutrophils, DCs and eosinophils into the ears ([Figure 3D](#fig3){ref-type="fig"}).

Expression of *Card14* mRNA in the skin of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice 5d after tamoxifen injection was preferentially localised to the suprabasal layers of the epidermis ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). RNAscope analysis showed that *Tnfa* mRNA had a staining pattern resembling that of *Card14* mRNA ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). Co-staining with specific antibodies revealed that *Tnfa* mRNA was largely produced by keratinocytes, with some contribution by neutrophils ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). *Tnfa* mRNA was not detected in T cells in the skin. These results suggest that keratinocytes are the main source of TNF driving skin inflammation.

Blocking of IL-17A also resulted in a significant reduction in epidermal thickness of the back skin, but did not significantly reduce epidermal thickness in the ears ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} and [Figure 3B](#fig3){ref-type="fig"}). The expression of pro-inflammatory cytokines and chemokines in the ears was not altered by anti-IL-17A, although *S100a9* mRNA was reduced ([Figure 3C](#fig3){ref-type="fig"}). Anti-IL-17A reduced *Cxcl3* and *S100a9* mRNAs in the back skin of *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice, but did not significantly alter the mRNA expression of the other cytokines and chemokines assayed ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}).

Together these results indicated that the acute inflammatory skin phenotype induced by tamoxifen injection of *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/*+*^ mice was predominantly driven by TNF produced by keratinocytes, while IL-17A appeared to play a less important role. These findings were consistent with the lack of requirement for adaptive immune cells for *Card14*^E138A^ to induce acanthosis and expression of pro-inflammatory genes in the skin, since αβ and γδ T cells are a major source of IL-17A in psoriasis ([@bib44]). Consistent with this, *Il17a* mRNA levels were not increased in ears of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^*Rag1*^-/-^ mice following tamoxifen induction ([Figure 2H](#fig2){ref-type="fig"}).

Comparison of the inflammatory effects of acute versus chronic CARD14^E138A^ expression {#s2-5}
---------------------------------------------------------------------------------------

Histological and flow cytometric analyses of ears revealed clear evidence of acanthosis and skin inflammation, respectively, 5d following tamoxifen injection of *Card14^LSL-E138A/+^ Rosa26^CreERT2/+^* mice ([Figure 1](#fig1){ref-type="fig"}), but externally the ears appeared normal ([Figure 4A](#fig4){ref-type="fig"}). However, one month (1 m) after CARD14^E138A^ induction, large scales with sharply demarcated edges were clearly evident on the ears of the mutant mice ([Figure 4A](#fig4){ref-type="fig"}). No obvious external back skin phenotype was visible at 5d or 1 m. Histologic examination of ears revealed increased acanthosis at 1 m compared with 5d ([Figure 4B](#fig4){ref-type="fig"}). In contrast, epidermal thickening of the back skin, although still detected, was significantly reduced at 1 m compared to 5d ([Figure 4B](#fig4){ref-type="fig"}).

![Evolution of inflammatory disease in *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice over time.\
*Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice (Het) and *Card14*^+/+^ *Rosa26*^CreERT2/+^ controls (WT) were intraperitoneally injected with tamoxifen on days 0, 1 and 2. Mice were sacrificed and tissues analysed at 5d or 1 m following the first tamoxifen injection. (**A**) The backs of the ears were photographed. Photos shown are representative of numerous mice. (**B**) Epidermal thickness of ear and skin was measured from H and E stained tissue sections. Data shown are a pool of 14 independent experiments. (**C**) Flow cytometry was performed on ear and skin. Ear: data pooled from 6 independent experiments: WT, n = 31; Het 5d, n = 22; Het 1 m, n = 13. Skin: data pooled from 9 independent experiments: WT, n = 43; Het 5d, n = 32; Het 1 m, n = 18. Note: FACS data for d5 are the same as that shown in [Figure 1F](#fig1){ref-type="fig"} (**D**) Serum was collected and cytokine concentrations analysed by immunoplex array. Serum samples collected from 3 independent experiments. (**E**) Weight was monitored over time. *Card14*^+/+^ *Rosa26*^CreERT2/+^ (n = 5), *Card14* ^LSL-E138A/+^ *Rosa26*^CreERT2/+^ (n = 6). For each day, differences between groups analysed by Student's t-test. Data collected from a mixture of male and female mice. (**B-D**) Differences between WT, Het 5d, and Het 1 m were analysed by one-way ANOVA. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001; \*\*\*\*, p\<0.0001.](elife-56720-fig4){#fig4}

Flow cytometry was used to compare immune cell infiltration in the ears and back skin at 5d and 1 m post-tamoxifen injection ([Figure 4C](#fig4){ref-type="fig"}). At 5d, the immune cell infiltrates in the ears and skin was largely composed of innate cells, with substantially increased numbers of neutrophils, macrophages, dendritic cells and NK cells. The number of αβ T cells was only modestly increased (approximately two-fold) at 5d in ears, but not altered in back skin. However, the numbers of αβ T cells, including Tregs, were substantially increased in both ears and back skin at 1 m. CARD14^E138A^ expression did not increase numbers of γδ T cells in ears or back skin at either time point.

Analysis of serum levels of TNF, IL-6 and IL-17A also revealed clear differences between 5d and 1 m post tamoxifen injection of *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice. Each of these cytokines was elevated at 5d, but reduced to WT levels at 1 m ([Figure 4D](#fig4){ref-type="fig"}). Paralleling the early systemic overproduction of pro-inflammatory cytokines, *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/*+*^ mice suffered a decrease in body weight between 6-7d post-tamoxifen, returning to control levels by 10d ([Figure 4E](#fig4){ref-type="fig"}).

To investigate the role of the adaptive immune system in skin pathology induced by prolonged CARD14^E138A^ signalling, *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^*Rag1*^-/-^ mice were analysed 1 m after tamoxifen injection. The absence of an adaptive immune system did not decrease ear and skin acanthosis, the abundance of S100A9^+^ myeloid cells or the levels of proinflammatory mRNA transcripts induced by CARD14^E138A^ ([Figure 4---figure supplement 1A--H](#fig4s1){ref-type="fig"}). Indeed, despite the absence of T and B cells, *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^*Rag1*^-/-^ mice compared to *Card14*^LSL-E138A/*+*^*Rosa26*^CreERT2/+^*Rag1*^+/+^ controls had significantly higher numbers of infiltrating NK, eosinophils and monocytes, while numbers of neutrophils and macrophages were similar ([Figure 4---figure supplement 1I](#fig4s1){ref-type="fig"}). Thus, the adaptive immune system was not required for skin inflammation induced by chronic CARD14^E138A^ signalling.

Taken together, these results suggest that acute CARD14^E138A^ signalling in keratinocytes induced the transient systemic release of pro-inflammatory mediators that produced body weight loss. This early inflammatory burst was accompanied by a skin infiltrate predominantly composed of innate immune cells. After this acute phase, the skin lesion evolved and external ear skin morphology became similar to plaque psoriasis in humans. Chronic CARD14^E138A^ signalling involved a prominent influx of T cells, although this was not required for induction of skin inflammation (from analysis of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/*+*^*Rag1*^-/-^ mice), and reduced levels of pro-inflammatory cytokines systemically. The progression of the pathology in the *Card14*^LSL-E138A/*+*^ *Rosa26*^CreERT2/+^ mice resembled the flares suffered by psoriatic patients, which eventually undergo spontaneous resolution ([@bib21]).

CARD14^E138A^ signalling induces dynamic changes in the skin transcriptome {#s2-6}
--------------------------------------------------------------------------

To gain more insight into the mechanisms by which CARD14^E138A^ induced skin inflammation, RNA was extracted from the ears of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ and *Card14*^+/+^*Rosa26*^CreERT2/+^ mice 5d and 1 m after tamoxifen injection and subjected to RNA sequencing analysis. A principal component analysis indicated that the main difference between sample groups was the genotype (PCA1); CARD14^E138A^ expression induced a genetic response clearly differentiated from the control groups ([Figure 5A](#fig5){ref-type="fig"}). The gene responses in the mutant mice were clearly distinct between 5d and 1 m, resulting in signalling duration being identified as the second cause of variation (PCA2) between sample groups ([Figure 5A](#fig5){ref-type="fig"}).

![Acute and chronic effects of CARD14^E138A^ signalling on gene transcription in the skin.\
*Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice (Het) and *Card14*^+/+^ *Rosa26*^CreERT2/+^ controls (WT) were intraperitoneally injected with tamoxifen on days 0, 1 and 2. Mice were sacrificed and tissues analysed at 5d or 1 m following the first tamoxifen injection (each experimental group n = 6). (**A**) Principal Component analysis separated samples by genotype (PCA1) and time point (PCA2). (**B**) Heatmap showing the top 500 differentially expressed genes. (**C**) Heatmap of the genes contained in the TNFα signalling via NF-κB (left), Naba Collagens (middle) and Keratinisation (right) pathways. (**D**) Graphs showing the expression levels of individual genes. TPM (Transcripts Per Million). Differences between WT, Het 5d and Het 1 m were analysed by one-way ANOVA. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001; \*\*\*\*, p\<0.0001.](elife-56720-fig5){#fig5}

458 genes were found to be upregulated and 88 genes downregulated more than 2-fold in the *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ compared to the controls at 5d. Interestingly, the pattern of gene expression changed between 5d and 1 m, as shown by the different colour intensities in the heat map, indicating a change in transcriptional pattern with prolonged CARD14^E138A^ signalling ([Figure 5B](#fig5){ref-type="fig"}). Pathway analysis revealed that TNF signalling via NF-κB was one of the pathways most strongly upregulated by CARD14^E138A^ at both 5d and 1 m ([Figure 5C](#fig5){ref-type="fig"}). Strikingly, pathways related to extracellular matrix formation were also largely reduced in the *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice at 5d compared to the other groups. Expression of keratinisation genes was enriched in the *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice relative to controls, especially at 1 m.

Among the genes more strongly upregulated by CARD14^E138A^ at 5d compared to 1 m were *Il6*, *Il1a, Osm, Mmp8, Il22*, *Ccl20*, Cxcl5, *Ccl17* and *Il17c* ([Figure 5D](#fig5){ref-type="fig"}). Several collagen genes (*Col11a1*, *Col6a6*, *Col13a1*, *Col14a1* and *Col16a1*) were downregulated by CARD14^E138A^ at 5d and returned to WT levels by 1 m. These changes may be due to the effects of IL-17A (and possibly IL-17C) on the extracellular matrix ([@bib42]). Cornification genes (*Klk8, Casp14, Flg* and *Krt6a*) were upregulated at 1 m compared to 5d, which was likely a secondary effect of chronic CARD14^E138A^ signalling. *Krt6a* is implicated in psoriasis pathogenesis and is associated with the wound healing/regenerative phenotype seen in psoriasis ([@bib33]). Genes related to immune cells changed in line with the types of immune cell infiltrates seen at different time points ([Figure 4C](#fig4){ref-type="fig"}). *Ly6g* (a marker for neutrophils) was markedly upregulated at 5d, while markers for T cells (*Cd4, Cd8a* and *Foxp3*) were only upregulated at 1 m.

Together the results in this section indicated that conditional expression of CARD14^E138A^ in adult mice allowed the evolution of CARD14^E138A^-induced skin inflammation to be monitored. This involved downregulation of some key proinflammatory genes at 1 m, which may reflect a homeostatic response to chronic activation of CARD14^E138A^ signalling pathways. Importantly, several genes relevant to the pathology of psoriasis (*S100a9, Il1f9, Cxcl2, Il17a* and *Tnfa*) remained significantly elevated in *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice at 1 m and may be necessary in maintaining the inflammatory skin phenotype promoted by chronic CARD14^E138A^ signalling.

Comparison of the CARD14^E138A^ skin transcriptome with human psoriatic skin transcriptome {#s2-7}
------------------------------------------------------------------------------------------

To determine whether the transcriptional changes in the skin of *Card14*^LSL-E138/+^ *Rosa26*^CreERT2/+^ mice were similar to Psoriasis Vulgaris (PV), the CARD14^E138A^ skin transcriptome was compared with the lesional skin transcriptome of psoriatic patients ([@bib54]). This showed that the CARD14^E138A^ transcriptome at 5d and 1 m ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) had relatively low R^2^ coefficients of determination with the PV datasets (R^2^: 0.255 at 5d and R^2^: 0.185 at 1 m). Nevertheless, when comparing the differentially expressed genes (DEG; logFC ≥2, p-adj ≤0.05) from the ears of *Card14*^LSL-E138/+^ *Rosa26*^CreERT2/+^ mice after tamoxifen injection and the skin of PV patients, 34% and 30% of genes at 5d and 1 m, respectively, were shared with PV ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). This striking overlap suggested that the skin inflammation that develops in *Card14*^LSL-E138/+^ *Rosa26*^CreERT2/+^ mice after tamoxifen injection shares mechanistic similarities with PV.

Comparison of the PV skin transcriptome with the published skin transcriptome induced by constitutive ubiquitous expression of CARD14^ΔE138^ in mice ([@bib41]; [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}) also showed only low correlation (R^2^: 0.23), although the CARD14^ΔE138^-induced skin transcriptome was well correlated with that of *Card14*^LSL-E138/+^ *Rosa26*^CreERT2/+^ mice at both 5d (R^2^: 0.566) and 1 m (R^2^: 0.656) after tamoxifen injection ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). This suggested that CARD14^E138A^-induced skin inflammation in constitutive and inducible mouse models involved similar mechanisms.

The low correlation coefficients between transcriptomes of *Card14*^LSL-E138/+^ *Rosa26*^CreERT2/+^ mice and PV are likely caused by comparing between species ([@bib6]). Consistent with this, the tamoxifen-induced *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2^ skin transcriptome at 5d was strongly correlated (R^2^: 0.684) with the published IL-23-induced skin transcriptome in mice ([@bib18]; [Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}). The IL-23-induced psoriasiform dermatitis model is thought to most closely resemble human psoriasis ([@bib49]).

The *CARD14*^E138A^ mutation was identified in a patient with GPP. Comparison of the transcriptomes from the skin of this patient with patients with classical psoriasis revealed similar differences when compared to controls, with higher transcript levels associated with the more severe form of psoriasis ([@bib30]). Genes with logFC ≥2 (padj ≤0.05) in *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice at 5d and 1 m after tamoxifen injection were compared with genes upregulated 2-fold or more in PV and GPP ([@bib28]). The skin transcriptome of *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice shared more upregulated genes with GPP than PV at both 5d (7% and 3.5%, respectively) and 1 m (6.2% and 3.6%, respectively) ([Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). Moreover, *Steap1* and *Steap4* mRNAs were found to be significantly increased in the ears of *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice at 5d and 1 m following tamoxifen injection ([Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}). The expression of *STEAP1* and *STEAP4* mRNAs is elevated in three different pustular skin disorders in humans and thought to be important in the regulation of proinflammatory neutrophil-activating cytokines ([@bib36]). The minor involvement of the adaptive immune system in skin inflammation induced by CARD14^E138A^ and these transcriptomic similarities suggested that *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice might model some aspects of GPP.

Atopic dermatitis (AD) is the most common inflammatory skin disorder, driven by both terminal keratinocyte differentiation defects and strong type two immune responses ([@bib23]). It has been proposed that loss-of-function mutations in *CARD14* are associated with severe AD ([@bib43]), in contrast to the gain-of-function *CARD14* mutations that promote psoriasis. Comparison of the CARD14^E138A^-induced skin transcriptome with the lesional skin transcriptome of atopic dermatitis (AD) patients ([@bib54]) revealed only a weak correlation at 5d (R^2^: 0.221) and 1 m (R^2^: 0.17), similar to comparisons with the PV transcriptome and probably mainly reflecting mouse/human differences ([Figure 5---figure supplement 3A](#fig5s3){ref-type="fig"}).

To gain a clearer insight into whether skin inflammation in *Card14*^LSL-E138/+^ *Rosa26*^CreERT2/+^ mice resembled AD, DEG (logFC ≥2, padj ≤0.05) in *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice were compared with gene expression levels in normal, non-lesional and lesional skin of PV and AD patients ([Figure 5---figure supplement 3B](#fig5s3){ref-type="fig"}). Heat maps showed that a significant fraction of 5d and 1 m CARD14^E138A^ upregulated genes were highly expressed in PV patients (red genes). However, these genes were expressed at lower levels in AD patients. In addition, *IL17a*, *IL19*, *IL36a* ([@bib53]) and *IL36g* ([@bib10]), which are considered to be biomarkers of psoriatic skin, were all strongly upregulated in the skin of *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ ([Figure 5D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 3C](#fig5s3){ref-type="fig"}). In contrast, AD involves downregulation of cornification proteins (eg. *FLG* and *IVL*) and upregulation of the TH2 cytokines *IL4, IL5, IL33, TSLP* and *CCL24* ([@bib23]), which are not changed or follow opposite trends in *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice ([Figure 5D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 3C](#fig5s3){ref-type="fig"}). These comparative analyses were consistent with CARD14^E138A^ inducing a psoriasis-like skin inflammation and not skin inflammation with gene expression characteristics of AD.

Homozygous expression of *Card14*^E138A^ induces a severe systemic illness {#s2-8}
--------------------------------------------------------------------------

The majority of psoriasis-associated *CARD14* mutations identified are heterozygous suggesting that homozygous expression of such CARD14 mutations might exceed a threshold of NF-κB activation that is compatible with life. To investigate whether the inflammatory effects of CARD14^E138A^ were dose dependent, the responses of *Card14*^LSL-E138A/LSL-E138A^*Rosa26*^CreERT2/+^ (homozygous) mice to tamoxifen injection were compared with *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ (heterozygous) mice.

Tamoxifen injection of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice did not result in any significant weight changes up to 4d ([Figure 6A](#fig6){ref-type="fig"}). In contrast, *Card14^LSL-E138A/LSL-E138A^ Rosa26^CreERT2/+^* mice started losing weight around 3d after tamoxifen induction. By 5d, homozygous mice had lost near to 20% of their initial body weight ([Figure 6A](#fig6){ref-type="fig"}), reaching humane end-points and requiring sacrifice. Upon general inspection, homozygous mice at d5 appeared scaly, emaciated, inactive and hunched, while heterozygous mice remained in good health.

![Induction of CARD14^E138A^ in *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice induces a severe inflammatory phenotype.\
*Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice (Het), *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice (Hom) and *Card14*^+/+^ *Rosa26*^CreERT2/+^ controls (WT) were intraperitoneally injected with tamoxifen on d0, 1 and 2. All mice were sacrificed 5d after the first injection of tamoxifen and tissues collected for analysis. (**A**) Weight was monitored every day. WT (n = 24, from five independent experiments), Het (n = 22, from five independent experiments), Hom (n = 49, from nine independent experiments). (**B**) The temperatures of all mice were taken using a rectal thermometer on d5. WT from four independent experiments, Het from two independent experiments, Hom from six independent experiments. (**C**) Representative histology images of colons stained with H and E (upper panels) or anti-S100A9 (lower panels) are shown. (**D**) Epidermal thickness of ear at d5 was measured from H and E stained tissue sections. Data collected from 15 independent experiments. (**E**) Flow cytometry was performed to calculate neutrophil numbers in ears at d5. Data pooled from two independent experiments. (**F**) qRT-PCRs of d5 ear and lung tissue were performed. Fold changes were calculated by comparison with the WT mice group. Data pooled from two independent experiments. (**G**) S100A9 staining was performed via immunohistochemistry to enumerate myeloid cell numbers in kidney, liver, and lung at d5. Data pooled from two independent experiments. (**H**) Serum was taken at the point of sacrifice and analysed by immunoplex array. (**I**) Serum quantification of biochemistry for indicators of liver (ALT: alanine aminotransferase and GLDH: glutamate dehydrogenase) and kidney (inorganic phosphate) damage. Sera were collected from 4 (H and I) independent experiments. Data collected from a mixture of male and female mice. (B, D-I) Differences between WT, Het, and Hom analysed by one-way ANOVA. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001; \*\*\*\*, p\<0.0001. (**C**) Scale bar = 200 µm.](elife-56720-fig6){#fig6}

The fraction of body surface covered by visible scales appeared to be greater in the homozygous mice than their heterozygous littermates. The middle and lower back skin of the heterozygous mice was largely clear of visible scaling, although areas of skin that were easily accessible to the mice (upper back and beneath the chin) often presented fine scales. In contrast, large areas of back skin in the homozygous mice, including sections less easy to scratch, were covered in fine scales ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). The skin of some homozygotes also appeared erythrodermic. The ears of the homozygous mice were visibly scalier than those of the heterozygotes, although the foot pads of both genotypes were similarly affected ([Figure 6---figure supplement 1B and C](#fig6s1){ref-type="fig"}). Of particular note, the lips of the d5 homozygous mice were consistently chapped ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}), while the lips of the heterozygous mice appeared normal.

On d5, homozygous mice were cold to the touch and measurement of rectal temperature confirmed hypothermia ([Figure 6B](#fig6){ref-type="fig"}). In contrast, rectal temperatures of heterozygous mice were similar to WT controls. Frequently, homozygous mice developed diarrhoea and dissection revealed that small and large intestines and caecum were filled with runny yellow fluid and occasional pockets of gas ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). Despite this apparent gut phenotype, histological analysis of small intestine (not shown) and colon ([Figure 6C](#fig6){ref-type="fig"}) did not reveal any gross tissue damage. Although homozygous mice appeared emaciated and dehydrated, the stomachs were full of food and much enlarged. The livers of the homozygous mice often appeared unusually pale. Histological examination of the ear and lower back skin revealed a similar extent of acanthosis present in heterozygous and homozygous mice ([Figure 6D](#fig6){ref-type="fig"}). Hence, while body surface involvement, as measured by visible external scaling, was greater in the homozygous mice, epidermal thickening was comparable between genotypes.

Flow cytometry showed increased neutrophil infiltration into the ears of the homozygous mice as compared to the heterozygotes ([Figure 6E](#fig6){ref-type="fig"}). Moreover, qRT-PCR analysis of d5 ear mRNA revealed a gene dosage effect of *Card14*^E138A^ for the majority of genes analysed and the expression of key psoriasis associated genes was higher in homozygous mice than in heterozygous mice ([Figure 6F](#fig6){ref-type="fig"}). Immunohistochemical analyses revealed significantly higher infiltration of S100A9^+^ myeloid cells in kidney, liver, colon, and lung in homozygous mice compared to heterozygotes ([Figure 6C](#fig6){ref-type="fig"}, lower panels and 6G). The mRNA expression of several pro-inflammatory genes, including *Ccl20*, *Cxcl2*, *S100A9* and *Il17c*, was also significantly increased in the lungs of homozygous mice, but not heterozygous mice, compared to WT controls ([Figure 6F](#fig6){ref-type="fig"}). Analyses of sera demonstrated that circulating levels of TNF and IL-1α were increased in homozygous mice compared to heterozygotes and there was a trend toward increased IL-6 levels ([Figure 6H](#fig6){ref-type="fig"}). Similarly, serum ALT (alanine aminotransferase), GLDH (glutamate dehydrogenase) and inorganic phosphate were significantly elevated in the homozygous, but not heterozygous mice ([Figure 6I](#fig6){ref-type="fig"}). Increased circulating levels of ALT and GLDH are indicative of liver damage, while increased inorganic phosphate is indicative of defective kidney function ([@bib57]). These results suggested multi-organ dysfunction in d5 homozygous mice.

In conclusion, the results in this section indicated that homozygous expression of *Card14*^E138A^ in adult mice caused a severe systemic illness, in addition to widespread skin inflammation. This phenotype had striking similarities to the systemic phenotype displayed in exacerbations of GPP ([@bib2]).

Keratinocyte-intrinsic CARD14^E138A^ signalling induces systemic inflammation independently of adaptive immune cells {#s2-9}
--------------------------------------------------------------------------------------------------------------------

Immunoblotting analyses demonstrated that the skin and gastrointestinal tract were the main sites of WT CARD14 expression ([Figure 1A](#fig1){ref-type="fig"}). RNAscope analysis of the colon revealed *Card14* expression to be largely restricted to the single layer of epithelial cells lining the gut lumen ([Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). Furthermore, *Card14* mRNA expression was found to increase from proximal to distal ends of the colon ([Figure 6---figure supplement 2B--D](#fig6s2){ref-type="fig"}).

The colons of *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice exhibited infiltration of S100A9^+^ myeloid cells at 5d after tamoxifen and increased expression of mRNAs encoding proinflammatory cytokines ([Figure 6---figure supplement 2E--F](#fig6s2){ref-type="fig"}). Given the unusual gut phenotype observed in homozygous *Card14*^LSL-E138A/LSL-E138A^*Rosa26*^CreERT2/+^ mice following tamoxifen injection, it was possible that gut-specific expression of CARD14^E138A^ was driving the severe systemic phenotype.

To investigate this, *Card14*^LSL-E138A/LSL-E138A^ *Villin*^CreERT2^ were generated to restrict CARD14^E138A^ expression to the epithelial cells of the gut. Tamoxifen injection of the resulting *Card14*^LSL-E138A/LSL-E138A^ *Villin*^CreERT2^ mice, induced expression of CARD14^E138A^ only in intestinal epithelial cells ([Figure 6---figure supplement 2G](#fig6s2){ref-type="fig"}). *Card14*^LSL-E138A/LSL-E138A^ *Villin*^CreERT2^ mice exhibited no gross phenotype at d5 after tamoxifen and were healthy ([Figure 7A](#fig7){ref-type="fig"}), with no signs of skin disease or organ dysfunction, and presented a histologically normal colon even 1 m after induction ([Figure 6---figure supplement 2H](#fig6s2){ref-type="fig"}). Tamoxifen injection induced expression of *Ccl20*, *Tnfa* and *Nos2* mRNAs in the gut of *Card14*^LSL-E138A/LSL-E138A^ *Villin*^CreERT2^ mice resulting from CARD14^E138A^ signalling in gut epithelial cells ([Figure 6---figure supplement 2I](#fig6s2){ref-type="fig"}). These results suggested that CARD14^E138A^ signalling in the gut was not sufficient to promote skin inflammation or the systemic inflammatory phenotype.

![CARD14^E138A^ signalling in keratinocytes induces a severe systemic phenotype independently of the adaptive immune system.\
Mice of indicated genotypes were intraperitoneally injected with tamoxifen on d0, 1 and 2. (**A**) Weight was monitored over time.* Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ (n = 49, from nine independent experiments), *Card14*^LSL-E138A/LSL-E138A^ *Krt14*^CreERT2^ (n = 6, from two independent experiments), and *Rag1*^-/-^*Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice (n = 11, from two independent experiments) lost weight, necessitating sacrifice 5d after the first injection of tamoxifen. *Card14*^LSL-E138A/LSL-E138A^ *Villin*^CreERT2^ mice (n = 7, from two independent experiments) and *Card14*^+/+^ *Villin*^CreERT2^ controls (n = 19, from four independent experiments) were monitored for an extended period and did not lose weight. (**B**) Temperatures of indicated mice were taken by rectal thermometer 5d after the first injection of tamoxifen. *Card14*^+/+^ *Krt14*^CreERT2^, and *Card14*^LSL-E138A/LSL-E138A^ *Krt14*^CreERT2^, from two independent experiments; *Rag*^+/+^ *Card14*^+/+^ *Rosa26*^CreERT2^, from four independent experiments; *Rag*^-/-^ *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2^, from one experiment. Differences between groups analysed by Student's t-test. (**C**) Numbers of S100A9^+^ myeloid cells were calculated from stained sections of lung tissue taken from indicated genotypes on d5. *Card14*^+/+^ mice represent a mixture of *Card14*^+/+^ *Rosa26*^CreERT2/+^ and *Card14*^+/+^ *Krt14*^CreERT2^ mice. Data pooled from two independent experiments. Differences between groups analysed by one-way ANOVA. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001.](elife-56720-fig7){#fig7}

To determine whether CARD14^E138A^ signalling in keratinocytes was driving the severe systemic phenotype, homozygous *Card14*^LSL-E138A/LSL-E138A^*Krt14*^CreERT2^ mice were generated. Tamoxifen injection of these mice rapidly induced a pronounced loss of weight, comparable to that in *Card14*^LSL-E138A/LSL-E138A^*Rosa26*^CreERT2/+^ mice ([Figure 7A](#fig7){ref-type="fig"}). *Card14*^LSL-E138A/LSL-E138A^*Krt14*^CreERT2^ mice also became hypothermic following tamoxifen administration and displayed significant infiltration of S100A9^+^ myeloid cells in the lungs ([Figure 7B and C](#fig7){ref-type="fig"}). Upon dissection, these mice also showed signs of organ dysfunction, most notably swollen stomach and intestines (data not shown), akin to those seen in the *Card14*^LSL-E138A/LSL-E138A^*Rosa26*^CreERT2/+^ mice ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). These results indicated that keratinocyte-intrinsic CARD14^E138A^ signalling was sufficient to induce severe systemic inflammation.

To determine whether the adaptive immune system contributed to the development of systemic disease induced by homozygous CARD14^E138A^ expression, *Card14*^LSL-E138A/LSL-E138A^*Rosa26*^CreERT2/+^ *Rag1*^-/-^ mice were generated. The absence of T and B cells in these mice did not ameliorate the systemic phenotype induced by homozygous *Card14*^LSL-E138A^, as judged by weight loss, hypothermia and extensive infiltration of S100A9^+^ myeloid cells into the lungs ([Figure 7A--C](#fig7){ref-type="fig"}). Hence, the rapid development of systemic disease in homozygous *Card14*^LSL-E138A/LSL-E138A^*Rosa26*^CreERT2/+^ mice following tamoxifen injection was not dependent on the adaptive immune system.

Anti-TNF ameliorates severe disease in homozygous *Card14*^LSL-E138A/LSL-E138A^*Rosa26*^CreERT2/+^ mice {#s2-10}
-------------------------------------------------------------------------------------------------------

Blocking TNF significantly reduced skin inflammation in heterozygous *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ mice following tamoxifen injection ([Figure 3](#fig3){ref-type="fig"}). *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice were treated with anti-TNF blocking antibody prior to and post tamoxifen induction to determine whether the severe systemic disease was also mediated by TNF. Weight loss was significantly reduced by anti-TNF treatment compared to isotype control, but not completely blocked ([Figure 8A](#fig8){ref-type="fig"}). However, anti-TNF prevented the hypothermic response of *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice to tamoxifen-induction ([Figure 8B](#fig8){ref-type="fig"}), which correlated with the mice appearing more active than isotype controls. Recruitment of S100A9^+^ myeloid cells into the kidneys, liver and lung at d5 post-tamoxifen was also significantly reduced by anti-TNF compared to isotype control ([Figure 8C](#fig8){ref-type="fig"}).

![Anti-TNF ameliorates severe systemic phenotype induced in *Card14*^LSL-E138A/LSL-E138A^*Rosa26*^CreERT2/+^ mice *Card14*^LSL-E138A/LSL-E138A^*Rosa26*^CreERT2/+^ mice were intraperitoneally injected with tamoxifen on d0, 1 and 2 and intraperitoneally injected with either isotype control, anti-TNF, or anti-GR1 on days −1, 1 and 3.\
Mice were sacrificed on d5. (**A**) Mouse weight was monitored from d0 until the experiment end. Isotype (n = 24, from four independent experiments), anti-TNF (n = 11, from two independent experiments), anti-GR1 (n = 11, from two independent experiments). For each day, differences between groups were analysed by one-way ANOVA. (**B**) Mouse temperatures were taken by rectal thermometer on d5. *Card14*^+/+^ control mice are a mixture of Cre-, *Rosa26*^CreERT2/+^ and *Krt14*^CreERT2^ mice (from four independent experiments). *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice: isotype (from four independent experiments), anti-TNF (from two independent experiments), anti-GR1 (from two independent experiments). (**C**) Numbers of S100A9^+^ myeloid cells were calculated from stained sections of kidney, liver, and lung tissue taken from isotype, anti-TNF or anti-GR1 treated *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice and *Card14*^+/+^ *Rosa26*^CreERT2/+^ (not antibody treated) controls. Data pooled from three independent experiments. (**D**) qRT-PCR was performed on d5 ear and lung tissue from *Card14*^+/+^*Rosa26*^CreERT2/+^ control mice and *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice treated with either isotype control IgG or anti-TNF. Fold changes were calculated by comparison with the *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ isotype treated group One representative experiment of 2 is shown. (**E**) Serum quantification of biochemistry for indicators of liver (ALT: alanine aminotransferase and GLDH: glutamate dehydrogenase) and kidney (inorganic phosphate) damage. Sera were collected from nine independent experiments. Differences between groups analysed by one-way ANOVA (A-E). \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001, \*\*\*\*, p\<0.0001.](elife-56720-fig8){#fig8}

Anti-TNF treatment significantly decreased ear mRNA expression of *Ccl20*, *Cxcl2* and *Cxcl3* ([Figure 8D](#fig8){ref-type="fig"}), the products of which are chemoattractants for neutrophils ([@bib7]). The reduction in expression of these genes by anti-TNF was even more pronounced in the lungs. mRNA expression of *S100a9*, a marker of myeloid cell infiltration, was also significantly reduced ([Figure 8D](#fig8){ref-type="fig"}).

Reactive oxygen species (ROS) generation, degranulation and formation of NETs (neutrophil extracellular traps) by neutrophils in the skin contribute to the inflammatory pathogenesis of psoriasis ([@bib7]). Anti-TNF reduction in S100A9^+^ myeloid cell infiltration into the liver, kidneys and lungs of *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice suggested that reduction in myeloid cell-mediated inflammation might explain in part the protective effect of anti-TNF treatment. To investigate this, *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice were administered anti-GR1 antibody, which depleted neutrophils and monocytes. Treatment with anti-GR1 before and during CARD14^E138A^ induction significantly reduced weight loss in the *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice, although not to the same extent as anti-TNF treatment ([Figure 8A](#fig8){ref-type="fig"}). However, at d5, anti-GR1 treated mice were completely protected from hypothermia ([Figure 8B](#fig8){ref-type="fig"}) and had significantly decreased S100A9^+^ myeloid cell infiltration into kidney, liver and lung ([Figure 8C](#fig8){ref-type="fig"}).

Biochemical analyses revealed that treating homozygous mice with either anti-TNF or anti-GR1, normalised ALT, GLDH and inorganic phosphate levels in the serum ([Figure 8E](#fig8){ref-type="fig"}). This suggested that these blocking antibody treatments protected homozygous mice from organ dysfunction.

Together these results indicated that in *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice, CARD14^E138A^ signalling in keratinocytes induced systemic release of TNF, which promoted recruitment of myeloid cells into vital organs via increased expression of chemokines. Myeloid cells in combination with upregulated expression of pro-inflammatory genes led to organ dysfunction and severe disease.

Discussion {#s3}
==========

Gain-of-function *CARD14* mutations are linked to the development of plaque psoriasis and generalised pustular psoriasis (GPP). *CARD14* variants are also associated with pityriasis rubra pilaris, a rare papulosquamous disorder phenotypically related to psoriasis ([@bib27]). In the present study, a conditional knock-in *Card14*^E138A^ mouse strain was used to determine how the highly penetrant psoriasis-associated *CARD14*^E138A^ mutation induces inflammation in adult mice. The effects of CARD14^E138A^ signalling were found to be dose-dependent. Tamoxifen induction of CARD14^E138A^ in heterozygous *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ mice induced skin inflammation phenotypically similar to psoriasis, while homozygous *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice developed skin inflammation and a severe systemic disease. Both phenotypes were driven by CARD14^E138A^ signalling in keratinocytes and dependent on TNF.

Earlier immunohistochemical studies showed that CARD14 protein was expressed in the basal layer in human skin ([@bib30]). In contrast, our analyses of mouse skin found that CARD14 was expressed at low levels in undifferentiated keratinocytes, and its expression increased with differentiation both at the RNA and protein level. These results suggest that the localisation of CARD14 expression differs between mouse and human skin. However, the present study also found that CARD14 protein expression increased in human keratinocytes differentiated in vitro. Furthermore, a similar trend was found in publicly available RNA sequencing datasets in which human keratinocytes were differentiated in vitro (GSE73305) and in organotypic epidermal tissue (GSE52954). It will be important to determine whether CARD14 protein levels similarly increase as keratinocytes differentiate in human skin. Nevertheless, regardless of apparent differences in CARD14 distribution between mouse and human, the predominant localisation of CARD14 in the skin is consistent with a function in sensing harmful stimuli, such as pathogens, at the interface between the organism and the environment.

Psoriasis-associated *CARD14* mutations are not linked with inflammatory gut phenotypes, although CARD14 is also expressed at high levels in the gastro-intestinal tract in humans ([@bib16]). RNAscope analyses showed that CARD14 is expressed in intestinal epithelial cells (IECs). Consistent with this, tamoxifen induction of CARD14^E138A^ in *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ mice promotes the expression of pro-inflammatory genes and recruitment of S100A9^+^ myeloid cells in the colon. However, CARD14^E138A^ expression in the colon was not sufficient to cause any gut tissue damage. These results are similar to the effects of expressing a constitutively active IKK2 mutant in IECs in IKK2\[EE\]^IEC^ mice, which also induces expression of pro-inflammatory cytokines in the gut and inflammatory cell infiltration without causing overt tissue damage ([@bib22]). IKK2\[EE\]^IEC^ mice, however, develop destructive acute inflammation, with intestinal barrier disruption and bacterial translocation following dextran sulfate sodium (DSS) or lipopolysaccharide (LPS) administration ([@bib22]; [@bib58]). Thus, additional insults might be required for CARD14^E138A^ signalling to induce a gut pathology.

Psoriasis can present as a mild stable disease with sharply demarcated psoriatic plaques in the skin at the prototypical body sites (e.g. elbows, knees, scalp) that predominantly involves the adaptive immune system. Alternatively, psoriasis can be an active severe disease with extensive body surface coverage, involving elevated levels of cytokines and inflammatory markers in the blood and systemic inflammation ([@bib8]; [@bib45]). This is mainly driven by cells of the innate immune system ([@bib35]). Acute induction of CARD14^E138A^ in *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice induced widespread skin lesions in back skin and ears that lacked defined borders. This primarily involved infiltration of innate immune cells into the skin and did not require adaptive immune cells. Prolonged CARD14^E138A^ signalling in *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice promoted the development of clearly delineated plaques on the ears with reduced acanthosis in back skin, suggesting less severe skin disease overall. These changes correlated with decreased skin expression of pro-inflammatory genes, decreased serum levels of key pro-inflammatory cytokines and more extensive infiltration of T cells into the skin. Acute expression of CARD14^E138A^ in *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ and *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice, therefore, appeared to model aspects of active psoriasis. In contrast, chronic CARD14^E138A^ signalling in *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ mice resulted in a phenotype more similar to mild, stable disease in psoriatic patients. Further research using this model will help to elucidate what factors mediate the transition from acute to chronic lesion.

The fold changes of the majority of proinflammatory genes analyzed at d5 in *Card14*^LSL-E138A/+^*Krt14*^CreERT2/+^ with respect to controls were lower than the fold changes of the *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice. The *Krt14*^CreERT2^ driver can induce 'leaky' expression of Cre ([@bib56]) consistent with some *Card14*^E138A/+^ *Krt14*^CreERT2/+^ mice presenting with an inflammatory skin phenotype without tamoxifen injection. Although such mice were excluded from our analyses, it is possible that low concentrations of active Cre in uninduced mice resulted in the expression of limiting amounts of CARD14^E138A^ which chronically activated NF-κB without promoting overt skin inflammation. This may have reduced the fold changes after tamoxifen injection due to negative feedback regulation as seen at 1 m post-tamoxifen injection in *Card14*^LSL-E138A/+^ *Rosa26*^CreERT2/+^ mice. It is also possible that reduced tamoxifen-induction of skin gene expression in *Card14*^E138A/+^ *Krt14*^CreERT2/+^ mice was due to differences to different expression levels of Cre protein between the two Cre-drivers, which use distinct promoters. Regardless, the induced genes were the same in both Cre drivers and the phenotype of both het and hom mice in the *Krt14*^CreERT2/+^ background was similar to the *Rosa26*^CreERT2/+^ histologically and systemically demonstrating that CARD14^E138A^ signalling in keratinocytes alone is sufficient to induce skin and systemic inflammation.

Earlier studies have described the phenotypes of knock-in mice constitutively expressing activated CARD14 variants ([@bib41]; [@bib52]; [@bib59]). Heterozygous *Card14*^ΔE138/+^, *Card14*^E138A/+^ and C*ard14*^ΔQ136/+^ mice develop skin inflammation similar to heterozygous *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice following tamoxifen induction. In both *Card14*^ΔE138/+^ and C*ard14*^ΔQ136/+^mice, blocking the IL-17A/IL-23 axis ameliorates skin inflammation. Anti-IL-17A also reduced the acanthosis that develops in the back skin of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice 5d after tamoxifen induction, but did not reduce acanthosis in ears or profoundly alter expression of pro-inflammatory genes. Acute induction of skin inflammation by CARD14^E138A^, therefore, is relatively independent of IL-17A and rather driven by overproduction of TNF by keratinocytes. Furthermore, inducible expression of CARD14^E138A^ promoted the acute and chronic development of skin inflammation independently of adaptive immune cells (and T cell production of IL-17A). It will be important to test whether anti-TNF treatment could prevent chronic skin inflammation induced by CARD14^E138A^.

The absence of a requirement for adaptive immune cells for the development of skin inflammation in *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice contrasts with a published study by Wang et al. where the inflammatory skin phenotype in mice constitutively expressing CARD14^ΔQ136^ was reduced by RAG1 deficiency. However, our data resemble other murine models of skin inflammation originating from constitutive signalling in keratinocytes where the absence of adaptive immune cells does not ameliorate skin disease and can even exacerbate it ([@bib32]; [@bib55]). Accordingly, in the absence of Tregs, innate immune cells play a more significant role in the imiquimod-induced psoriasis-like skin pathology ([@bib24]; [@bib48]). C*ard14*^ΔQ136/+^ mice only displayed a histopathologic phenotype in tail skin, but not ear skin. It is possible that the adaptive immune system plays different roles in these different anatomical regions. Alternatively, the inflammatory skin phenotype that develops in C*ard14*^ΔQ136/+^ mice may involve developmental alterations that occur in utero that require adaptive immune cells.

Systemic disease was not described in mice constitutively expressing the CARD14^E138A^ variants ([@bib41]; [@bib52]; [@bib59]), with all analyses focusing only on inflammatory skin phenotypes . However, heterozygous *Card14*^E138A/+^ mice have reduced survival after birth, while *Card14*^ΔE138A/ΔE138A^ mice die in utero or shortly following birth. It is possible that variant CARD14 signalling during early life induces a severe, systemic disease in these strains that decreases survival. In addition, in utero expression of variant CARD14 could mean that, by the time of analysis of surviving adult mice, the disease state may have already developed from severe/active to mild/stable. In line with this, the inflammatory back skin phenotype, which coincided with severe disease in *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice, was not evident in constitutive *Card14*^ΔQ136/+^ mice, and only briefly detected (between 5 and 7 days of age) in constitutive *Card14*^ΔE138A/+^ mice ([@bib59]).

Our analyses of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ mice and *Card14* ^LSL-E138A/\ LSL-E138A^ *Rosa26*^CreERT2/+^ mice revealed a *Card14^E138A^* gene dosage effect, with increased CARD14^E138A^ expression inducing a more severe acute phenotype. This presumably explains why *CARD14* psoriasis-associated mutations are generally heterozygous. Weaker NF-κB activating variants, such as *CARD14*^G117S^, have been found in their homozygous forms in children with severe psoriasis suggesting that the overall level of NF-κB activation is important ([@bib9]; [@bib27]; [@bib51]). Genetic background also contributes to the penetrance of gain-of-function *CARD14* mutations in promoting psoriasis ([@bib3]), as recently confirmed in mouse studies in which the survival of mice with a constitutive *Card14*^E138A^ mutation is increased by crossing C57BL/6 mice onto a 129S4 background ([@bib52]).

The severe, systemic disease that developed in homozygous *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice following tamoxifen induction had similarities with exacerbations in GPP patients. These included skin disease that covered the majority of the body surface and hypothermia, the mouse equivalent of human fever ([@bib20]). The extensive scaling of mutant mouse lips also appeared to resemble cheilitis, a common manifestation of GPP ([@bib40]). Although pustules were not macroscopically visible (perhaps reflecting differences between human and mouse skin), histological analysis revealed extensive pustule formation within the epidermis and stratum corneum following CARD14^E138A^ expression. *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice also presented with myeloid cell infiltration in multiple vital organs and evidence of multi-organ dysfunction, similar to patients with GPP. The skin transcriptome of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ mice also shared similarities with the skin transcriptome of the GPP patient expressing the *CARD14*^E138A^ variant. The increased expression of *Steap1* and *Steap4* mRNAs in the skin of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ mice after tamoxifen injection is particularly interesting since these genes have been found to be upregulated in several types of pustular psoriasis and are known to be important in neutrophil chemotaxis ([@bib36]). To our knowledge, *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice are the first to mimic the phenotypes of GPP and might be useful in future studies to understand more about the etiopathogenesis of this severe form of psoriasis.

Both GR1 antibody (to deplete neutrophils and monocytes) and TNF antibody significantly reduced disease severity in *Card14*^LSL-E138A/LSL-E138A^ *Rosa26*^CreERT2/+^ mice following tamoxifen administration. Current treatments for GPP patients include granulocyte/monocyte apheresis and anti-TNF ([@bib17]; [@bib31]) suggesting that *Card14*^LSL-E138A/LSL-E138A^*Rosa26*^CreERT2/+^ mice could be used for pre-clinical testing of new medicines for GPP treatment. The present study indicates that constitutive CARD14^E138A^ activation of NF-κB in keratinocytes is sufficient to promote skin inflammation and systemic inflammatory disease. This raises the possibility that it may be feasible to develop topical medicines that block CARD14 signalling in the skin to treat CARD14-induced psoriasis and systemic inflammation.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                                 Source or\                                                      Identifiers                                                              Additional\
  (species) or\                                                                 reference                                                                                                                                information
  resource                                                                                                                                                                                                               
  --------------------------------- ------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------
  Genetic Reagent (*M. musculus*)   *Card14*^LSL-E138A^                         Taconic                                                         MGI:6111507                                                              Mice were bred into the C57BL6/J background for \> 8 generations by the Ley lab. Strain name at the Francis Crick Institute\
                                                                                                                                                                                                                         SLAT.

  Genetic Reagent (*M. musculus*)   *Rosa26*^CreERT2^                           PMID:[12582257](https://www.ncbi.nlm.nih.gov/pubmed/12582257)   RRID:[IMSR_TAC:10471](https://scicrunch.org/resolver/IMSR_TAC:10471)     Strain name at the Francis Crick Institute\
                                                                                                                                                                                                                         BRAW

  Genetic Reagent (*M. musculus*)   *Villin*^CreERT2^                           PMID:[15282745](https://www.ncbi.nlm.nih.gov/pubmed/15282745)   RRID:[IMSR_JAX:020282](https://scicrunch.org/resolver/IMSR_JAX:020282)   Strain name at the Francis Crick Institute\
                                                                                                                                                                                                                         BRGU

  Genetic Reagent (*M. musculus*)   *Krt14*^CreERT2^                            PMID:[14742263](https://pubmed.ncbi.nlm.nih.gov/14742263/)      (MGI:4357971)                                                            Mice were bred into the C57BL6/J background for \> 8 (more like N5 for the SLDD12) generations by the Ley lab\
                                                                                                                                                                                                                         Strain name at the Francis Crick Institute\
                                                                                                                                                                                                                         SLBN

  Genetic Reagent (*M. musculus*)   *Rag1*^-/-^                                 PMID:[7926785](https://pubmed.ncbi.nlm.nih.gov/7926785/)        (MGI:2448994)                                                            Historically Backcrossed 12 x to C57BL/6J total N unknown\
                                                                                                                                                                                                                         Strain name at the Francis Crick Institute BRAU

  Gene (*M. musculus*)              *Card14*                                    *Mus musculus*\                                                 MGI:2386258                                                              
                                                                                Mouse Genome Informatics                                                                                                                 

  Cell line (*H. sapiens*)          NHEK                                        Lonza                                                           Cat \#00192627                                                           

  Antibody                          IgG1 isotype control (mouse monoclonal)     BioXcell                                                        MOPC-21                                                                  0.5 mg per injection

  Antibody                          Anti-Il17a (mouse monoclonal)               BioXcell                                                        clone 17F3                                                               0.5 mg per injection

  Antibody                          IgG2b isotype control (Rat monoclonal)      BioXcell                                                        LTF-2                                                                    0.5 mg per injection

  Antibody                          Anti-Gr1 (Rat monoclonal)                   BioXcell                                                        clone RB6-8C5                                                            0.5 mg per injection

  Antibody                          rat IgG1 isotype control (Rat monoclonal)   BioXcell                                                        TNP6A7                                                                   0.5 mg per injection

  Antibody                          Anti-TNFa (Rat monoclonal)                  BioXcell                                                        clone XT3.11                                                             0.5 mg per injection

  Antibody                          Anti-Ki67 (Rabbit monoclonal)               Abcam                                                           ab16667                                                                  1/350

  Antibody                          Anti-Involucrin (Rabbit monoclonal)         In house                                                        ERL-3                                                                    Produced by the Crick Cell Services.\
                                                                                                                                                                                                                         1/800

  Antibody                          Anti-S100a9 (Rat monoclonal)                In house                                                        2b10                                                                     1/1000 (Can be purchased from abcam ab105472)

  Antibody                          Anti-Endomucin (Rat monoclonal)             Santa Cruz                                                      sc-65495                                                                 1/400

  Antibody                          anti-FLAG (Mouse monoclonal)                Sigma                                                           F1804                                                                    1/1000

  Antibody                          anti-CARD14 (Rabbit polyclonal)             This paper                                                      CUK-1813                                                                 Produced by Covalab\
                                                                                                                                                                                                                         1/1000

  Antibody                          anti-Hsp90 (Rabbit polyclonal)              Santa Cruz                                                      sc-7947                                                                  1/5000

  Sequence-based reagent            *Card14* oligo 1                            This paper                                                      PCR oligo                                                                TCAACATTATCTTCCAAGCTCC

  Sequence-based reagent            *Card14* oligo 2                            This paper                                                      PCR oligo                                                                TGACCTCACGTTTCATGCG

  Commercial assay or kit           SuperScript VILO cDNA Synthesis Kit         Life Technologies                                               11754250                                                                 

  Commercial assay or kit           RNeasy mini kit                             Qiagen                                                          74106                                                                    

  Commercial assay or kit           LEGENDplex,                                 Biolegend                                                       740150                                                                   

  Commercial assay or kit           TaqMan Gene Expression Master Mix           Thermo Fisher                                                   4369514                                                                  

  Commercial assay or kit           *Card14* RNAscope                           ACDBio                                                          Probe - Mm-Card14 Cat No 476041                                          

  Chemical compound, drug           Corn oil                                    Sigma                                                           C8267                                                                    100 ul per injection

  Chemical compound, drug           Tamoxifen                                   Sigma                                                           T5648                                                                    2 mg per injection

  Software, algorithm               Image J                                     NIH,\                                                           RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)             <https://imagej.nih.gov/ij/>
                                                                                Bethesda, MD                                                                                                                             

  Software,\                        GraphPad Prism                              GraphPad Prism (<https://graphpad.com>)                         RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)             GraphPad Prism eight software\
  algorithm                                                                                                                                                                                                              for Mac
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

Mice were bred and maintained under specific pathogen--free conditions at the Francis Crick Institute. Experiments were performed in accordance with UK Home Office regulations and endorsed by the Francis Crick Institute Animal Welfare and Ethical Review Body under the Procedure Project Licence 70/8819. *Rosa26*^CreERT2^ ([@bib46]), *Krt14*^CreERT2^ ([@bib25]), *Villin*^CreERT2^ ([@bib15]) and *Rag1*^-/-^ ([@bib47]) mouse lines have been described previously.

The *Card14*^LSL-E138A^ mouse strain was made by Taconic (official strain name *Card14^tm1.1Abow^*). The targeting strategy allows the generation of a constitutive Knock-In (KI) of a 3xFLAG tag or a conditional Knock-In of a point mutation (KI-PM) in the *Card14* gene. The 3' part of intron 3, containing the splice acceptor site, and exons 4 to 22, including the 3'-untranslated region, (UTR) were flanked by loxP sites and inserted into intron 3 of the genomic *Card14* locus ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). An additional polyadenylation signal (hGHpA: human growth hormone polyadenylation signal) was inserted between the 3' UTR and the distal loxP site to prevent transcriptional read-through. The sequence for the 3xFLAG tag with linker (GGGS-DYKDHDGDYKDHDIDYKDDDDK) was inserted between the last amino acid and the translation termination codon in exon 22 of the wildtype *Card14* cDNA (fused to exons 4 to 22). The insertion allows the translation of a wildtype CARD14-3xFLAG tag fusion protein. The E138A mutation (GAG \>GCG) was introduced into exon 5 downstream of the distal loxP site. Positive selection markers were flanked by FRT (neomycin resistance - NeoR) and F3 (puromycin resistance - PuroR) sites and inserted downstream of the proximal loxP site and upstream of the distal loxP site. The targeting vector was generated using BAC clones from the C57BL/6J RPCIB-731 BAC library and was transfected into the Taconic Biosciences C57BL/6N Tac ES cell line.

Transgenic mice containing the construct were crossed to a Flp deleter strain to remove the neo selection cassette. The resulting *Card14*^LSL-E138A/LSL-E138A^ mice expressed the wild type CARD14-3xFLAG tag fusion protein from the endogenous *Card14* promoter and thus recapitulated the expression pattern of the *Card14* gene. These mice were crossed to the indicated inducible Cre driver strains. After tamoxifen-induced Cre-mediated recombination, the minigene was excised, resulting in expression of *Card14*^E138A^. Mouse genotyping was carried out by TransNetyx.

To verify tissue-specific Cre deletion, DNA extracted from ear snips or colon was used for genotyping by PCR (KAPA Taq PCR Kit). The fragment amplified with oligos 1 (TCAACATTATCTTCCAAGCTCC) and 2 (TGACCTCACGTTTCATGCG) detected the WT *Card14* locus (1818 bp), the Knock-In allele (1310 bp), and the mutant *Card14*^E138A^ allele after Cre deletion (1899bp).

In vivo procedures {#s4-2}
------------------

To induce expression of CARD14^E138A^, *Card14*^LSL-E138A/+^ mice, crossed to the appropriate CreERT2 driver strain, were given intraperitoneal (I.P.) injections of tamoxifen (Sigma) dissolved in corn oil (Sigma). Each mouse received a total of three I.P. injections (2 mg/injection) of tamoxifen over three consecutive days.

For all blocking antibody experiments, mice received I.P. injections of antibody on days −1, 1 and 3. In all cases, I.P. tamoxifen was given on days 0, 1 and 2. (On day 1, when mice received two I.P. injections, the blocking antibody was given in the morning and tamoxifen in the afternoon). Each antibody injection contained 0.5 mg of blocking antibody or isotype control. All antibodies were purchased from BioXcell. Mice in each experimental cohort were treated with either a blocking antibody or the appropriate isotype control. Antibody/isotype control combinations were as follows: TNF antibody (clone XT3.11) and rat IgG1 isotype control (TNP6A7); GR1 antibody (anti-Ly6G/Ly6C, clone RB6-8C5) and rat IgG2b isotype control (clone LTF-2); IL-17A antibody (clone 17F3) and mouse IgG1 isotype control (MOPC-21).

Flow cytometry {#s4-3}
--------------

Flow cytometric analyses were performed with 5 million splenocytes, 5 million cells from the lamina propria of the colon, 5 million cells from the epithelium of the colon, 4x skin punches (total surface area of approximately 200 mm^2^), or 1 ear.

Skin was shaved and excess fat scraped away from the dermis. Ears were split into dorsal and ventral halves to aid digestion. Skin and ears were finely minced. Each skin or ear sample was incubated (1 hr, 37°C, with vigorous shaking) in digestion cocktail (RPMI containing 0.4 mg/mL liberase TL (Roche), 1 mg/mL collagenase D (Roche), 50 ug/mL DNase I (Roche)).

Individual, whole colons were flushed with ice-cold PBS, cut into 0.5--1 cm long pieces, and washed thoroughly by vortexing in PBS. The epithelial cell layer was removed and collected by 2x incubation of tissue pieces in pre-digestion solution (1x HBSS, calcium and magnesium free, containing 10 mM HEPES, 5 mM EDTA, 2 mM DTT, 1% FCS, 1x penicillin-streptomycin) at 37°C, with vigorous shaking, for 20 min followed by sample straining and collection of the flow-through. Tissues pieces were then washed in HBSS with 5% FCS for 10 min at 37°C, with vigorous shaking, followed by further straining and collection of flow-through. Pooling of collected supernatants from the 2 pre-digestion steps and the washing step produced the colon epithelium sample (stained and analysed as below). Remaining tissue pieces (consisting of the colon lamina propria) were then minced and incubated in digestion solution (1x HBSS, with calcium and magnesium, containing 10 mM HEPES, 1% FCS, 1x penicillin-streptomycin, 50 ug/mL DNase I, 0.4 mg/mL Liberase TL) at 37°C, with vigorous shaking, for 30 min.

Digested skin, ear, colon lamina propria samples, and whole spleens were filtered through a 100 μm cell strainer to produce single cell suspensions. Cells were incubated in FcR block (anti-CD16/CD32, clone 93, Biolegend, 0.5 mg/mL) for 20 min at 4°C, followed by washing in PBS containing 0.1% BSA. Samples were then stained in saturating concentrations of antibodies diluted in PBS/BSA for 1 hr at 4°C, followed by washing in PBS/BSA. Samples were fixed in 4% paraformaldehyde (IC fixation buffer, eBioscience) for 15 min, followed by washing in PBS/BSA. Counting beads (CountBright Absolute counting beads, ThermoFisher Scientific) were added to samples prior to analysis on a BD LSR Fortessa X20. Compensation was performed with the aid of beads (Ultracomp eBeads, ThermoFisher Scientific). Data analysis was performed with FlowJo V10.5.3 software (Tree Star).

CD4 BV650 (clone RM4-5), CD8 BV510 (clone 53--6.7), CD11b BV605 (clone M1/70), CD11c PerCPcy5.5 (clone N418), CD25 APC (clone PC61), CD64 FITC (clone X54-5/7.1), MHC-II BV510 (clone M5/114.15.2), and TCRβ PerCPcy5.5 (clone H57-597) were purchased from Biolegend. CD19 APCcy7 (clone 1D3) and Ly6G PE (clone 1A8) were purchased from BD Pharmingen. CD45.2 APCef780 (clone 104), CD45.2 ef450 (clone 104), MerTK PEcy7 (clone DS5MMER), NK1.1 PEcy7 (clone PK136), and TCRγ/δ PE (clone eBioGL3) were purchased from eBioscience. Live/dead fixable blue dead cell stain was purchased from ThermoFisher Scientific.

For flow cytometric gating ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}), all populations were first gated on: single, live and CD45^+^ cells. Gating strategies for individual cell populations were then as follows: neutrophils: MHC-II^-^, CD11b^+^, Ly6G^+^; macrophages: Ly6G, MHCII^+^ and/or CD11b^+^, Ly6C+ and/or CD64^+^, MerTK^+^ CD64^hi^; dendritic cells (DCs): MHC-II^+^, CD11b^+^, CD11c^hi^; αβ T cells: TCRβ^+^; CD4 T cells: TCRβ^+^, CD4^+^; CD8 T cells: TCRβ^+^, CD8^+^; Tregs: TCRβ^+^, CD4^+^, CD25^+^; B cells: CD19^+^; γδ T cells: TCRγδ^+^; NK cells: NK1.1^+^.

Immunoplex array and serum biochemistry {#s4-4}
---------------------------------------

Blood was collected by cardiac puncture of dead mice. Blood was allowed to clot and serum separated by centrifugation. Cytokine and chemokine concentrations within serum samples were analysed by immunoplex array (LEGENDplex, Mouse Inflammation Panel, Biolegend) on a BD LSR Fortessa X20, following manufacturer's instructions.

Serum biochemistry was quantified by IDEXX bioanalytics.

Keratinocyte cultures {#s4-5}
---------------------

Primary mouse keratinocyte cultures were prepared from mouse tail skin. Tails were cut longitudinally and bone removed. After cutting into 3 segments, the pieces were floated in cold 5 mg/ml Dispase (Thermo Fisher, 17105--041) for 4 hr at 4°C. The epidermis was then separated with forceps, and washed in cold PBS twice. Epidermis was floated in TrypLE select (Thermo fisher, 12563011) for 10 min at 37°C to detach the keratinocytes. After TrypLE incubation, epidermis was further minced with forceps and aspirated through a pipette 20 times. The suspended keratinocytes were then transfered into a 50 ml falcon with a filter on the top (100 µm) and centrifuged to pellet the cells. Keratinocytes were cultured in 7 µg/ml Collagen 1 coated plates (Thermo Fisher, A1048301) with CNT-57 medium for 2 days and then changed to CNT-02 for 5d (CELLnTEC, Bern, Switzerland). The medium was changed every second day. Normal human epidermal keratinocytes (NHEK) were purchased from Lonza and cultured in CNT-57 medium.

For differentiation studies, cells were seeded in six-well plates (Thermo Fisher) and grown to pre-confluence, then 2 mM CaCl~2~ was added and lysates were obtained at the indicated culture times.

Histopathology and immunohistochemistry {#s4-6}
---------------------------------------

Excised Tissues were fixed in 10% neutral buffered formalin for 48 hr at RT, then stored in 70% ethanol. Tissues were embedded in paraffin and sections (5 μm) were stained with hematoxylin and eosin (H and E). Pictures were taken with a Nikon Eclipse 90i microscope. For acanthosis (epidermal thickness) quantification, 3 measurements from the basement membrane to the stratum corneum were taken for each 10x magnification picture using Image J (NIH, Bethesda). For each mouse, 3 pictures were taken.

For immunohistochemistry, tissue sections were dewaxed three times in xylene for 1 min. Slides were then immersed in a series of decreasing concentrations of ethanol (1 min incubations) ending with distilled water. Heat-mediated antigen retrieval was conducted for Ki67 (Abcam ab16667) and Involucrin (in house) staining. Briefly, slides were immersed in a preheated solution of pH 6 Citrate buffer and further heated for 15 min in a microwave. For S100A9 (2b10 clone; in house) staining, antigen retrieval involved incubation of slides in 0.1% Trypsin solution for 15 min at 37°C. After antigen retrieval, endogenous peroxidases were blocked in 1.6% H~2~O~2~ in PBS for 10 min followed by distilled water for 5 min. The corresponding normal serum diluted to 10% in 1%BSA/PBS was applied for 10 min, at RT. After blocking, anti-KI67 (1/350), anti-involucrin (1/800), anti-S100A9 (1/1000) or anti-Endomucin (Santa Cruz, sc-65495 1/400) was added to slides, which were incubated overnight at 4°C. Antibody excess was washed from slides by three PBS immersions. The corresponding HRP-linked secondary antibody was applied for 45 min at RT and then washed 3x with PBS. Avidin-biotin complex solution was applied for 30 min at RT and washed 3x with PBS. DAB solution was used to develop the signal and the reaction terminated with distilled water. To count dermal infiltrating cells (S100A9) or epidermal Ki67+ cells, three pictures per sample were randomly taken at 10x magnification, the number of infiltrating cells or Ki67^+^ cells were counted and the average between the three pictures calculated.

For *Card14* mRNA detection in tissue, RNAscope Probe - Mm-Card14 Cat No 476041 was used following manufacturer's instructions (ACDBio). For *Tnfa* mRNA detection in tissue, RNAscope Probe- Mm-TNFa Cat No. 311081 was used. For localisation of *Tnfa* with different cell types, the following antibodies were used: CK5 (Abcam, ab52635 at 1/6000) for keratinocytes; CD3 (Abcam, ab134096 at 1/750) for T cells and Ly6g (BD Pharmigen, 551459 at 1/500) for neutrophils. RNAscope staining was performed first, followed by IHC. Bound antibodies were visualised using Blue chromogen (Vector, SK-5300) for 3--15 min at RT.

Protein lysates and western blot {#s4-7}
--------------------------------

Mouse tissues were lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM sodium pyrophosphate, 50 mM sodium fluoride, 1 mM sodium vanadate, 0.1% SDS, 1% Triton-X, 0.5% deoxycholate and protease inhibitor cocktail (Roche 11836170001)). Protein levels were quantified (Pierce BCA protein assay, Thermo Scientific) and normalised. Lysates were boiled in Laemmli buffer, resolved by SDS-PAGE and transfered to a PVDF membrane (Trans-Blot Turbo Transfer Packs, Biorad). Membranes were blocked for 1 hr at RT with 5% skimmed milk and incubated with anti-FLAG M2 (Sigma F1804); or anti-Hsp90 (Santa Cruz; sc-7947). Bound HRP-labelled secondary antibody (anti-mouse IgG; Southern Biotech) was visualised by enhanced chemiluminescence (ECL, Millipore).

RNA extraction and quantification by RT-qPCR {#s4-8}
--------------------------------------------

Tissues were harvested and immersed in RNAlater (Thermofisher) for 48 hr at 4°C and then stored at −80°C. To extract RNA, the tissues were blended in the presence of trizol with IKA T25 digital Ultra-turrax tissue homogeniser. Chloroform was added and mixed vigorously. Following 15 min centrifugation at maximum speed at 4°C the aqueous phase was transferred to a RNeasy mini kit (Qiagen \#74106) to purify RNA, following manufacturer's instructions. Quantity and purity of RNA were analysed using a NanoDrop ND-1000 Spectrophotometer.

SuperScript VILO cDNA Synthesis Kit (Life Technologies \#11754250) was used to obtain cDNA from 1 μg of RNA. For RT-qPCR, QuantStudio 5 Real-Time PCR was used according to the instructions provided by the manufacturers. Induction of genes was calculated with the delta delta CT method, using *Hprt* as a housekeeping gene. Real-time quantitative PCR (qPCR) was performed using TaqMan Gene Expression Master Mix and predesigned probes (Thermo Fisher Scientific, Waltham, MA) for the following mouse genes: *Card14* (Mm00459947_m1), *S100a9* (Mm00656925_m1), *Tnf* (Mm00443258_m1), *Il1f9 (*Mm00463327_m1), *Il17c* (Mm00521397_m1), *Hprt* (Mm03024075_m1), *Il22* (Mm01226722_g1), *Il23a* (Mm01160011_g1), *Il17a* (Mm00439618_m1), *Ccl20* (Mm01268754_m1), *Cxcl2* (Mm00436450_m1), *Cxcl3* (Mm01701838_m1), *Nos2* (Mm00440485_m1). For human samples, *CARD14* (Hs01106904_m1), *18S* (Hs99999901_s1) and *IVL* (Hs00846307_s1) probes were used.

RNA-Seq and data analysis {#s4-9}
-------------------------

RNA was isolated from tissue as detailed above. RNA-sequencing was performed by the Crick advanced sequencing facility using the polyA KAPA mRNA Hyper Prep kit (Roche) and coding-mRNA as starting material. Sequencing was performed on an Illumina HiSeq4000 instrument with single end reads of at least 75 bp. The RNA-Seq data generated in this article was deposited in the GEO repository (GSE149880).

The 'Trim Galore!' utility version 0.4.2 was used to remove sequencing adaptors and to quality trim individual reads with the q-parameter set to 20 (<https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>). Then sequencing reads were aligned to the mouse genome and transcriptome (Ensembl GRCm38 release-89) using RSEM version 1.3.0 ([@bib34]) in conjunction with the STAR aligner version 2.5.2 ([@bib13]). Sequencing quality of individual samples was assessed using FASTQC version 0.11.5 (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) and RNA-SeQC version 1.1.8 ([@bib12]). Differential gene expression was determined using the R-bioconductor package DESeq2 version 1.14.1 ([@bib38]) (<http://www.R-project.org>). Gene set enrichment analysis (GSEA) was conducted as described in [@bib50].

Statistical analysis {#s4-10}
--------------------

Data were analysed using GraphPad Prism 8 software for Mac (GraphPad; La Jolla, CA, USA). To compare the mean values between two groups, unpaired two-tailed Student t-tests was used. Statistical differences in mean values between three or more experimental groups were determined with one-way ANOVA Tukey's multiple comparison test. p values \< 0.05 were considered statistically significant. Significance was noted in the graphs as stars: \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001 and \*\*\*\*p\<0.0001.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

In the skin disease psoriasis in humans, a mutation has been found in the CARD14 molecule. In the present paper, a murine model with this mutation *Card14*^E138A^ was developed. The study shows that induced expression of this mutant in the skin drives a psoriasis phenotype in mice. An important finding is that neutralization of TNFα is more effective than neutralization of IL-17A, at least in the acute phase. In addition, the investigations suggest that anti-inflammatory therapies that target CARD14 signaling in keratinocytes, rather than systemic biologicals, might be an effective treatment early in disease progression.

**Decision letter after peer review:**

Thank you for submitting your article \"CARD14^E138A^ signalling in keratinocytes induces TNF-dependent skin and systemic inflammation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Carla V Rothlin as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Jos van der Meer as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Ellen Vandenbogaard (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in *eLife* but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.

Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in *eLife*, either of which would be linked to the original paper.

Summary:

The authors developed and characterized an inducible murine model for *Card14*^E138A^, a psoriasis-associated mutation in humans. Importantly, this approach enables them to report that induced expression of this mutant in the skin is sufficient for driving a psoriasis phenotype in mice. They also find that neutralization of TNFα provides a more effective therapeutic effect than neutralization of IL-17A, at least in the acute phase. The authors also generated homozygous mutant mice, which display more severe systemic effects, demonstrating a clear gene dosage effect for this mutation. The study is of significant relevance to the field, well-designed and robustly performed. Below we outline a series of revisions to strengthen or clarify the authors\' conclusions.

Revisions for this paper:

1\) The authors have modeled a human mutation into the mouse *Card14* gene. Can the authors add a comparison on the murine gene and the human ortholog in terms of their homology?

2\) The authors defined the expression of CARD14 through western blot and RNAscope approaches. The results are in line with previously published murine data, as well as with single cell sequencing data from the Kaspar lab (http://kasperlab.org/mouseskin). However, the results seem to be in contrast to protein expression profiles reported in human skin, in which CARD14 protein is mostly found in basal cells (of note: Figure 1B also shows signal in basal cells). This requires a thorough analysis or at least a discussion on the differences between mice and human and potential consequences for disease mechanisms.

3\) Throughout the manuscript, the authors link their results to \'psoriasis\' (e.g. disease markers, therapeutic response). However, the investigated CARD14 mutation is related to GPP, not (or to a lesser extent) to other psoriasis endotypes like PV (Berki et al., 2015). The characterization of the inflammatory response includes several markers (e.g. KI67, S100A9, cytokines and chemokines). But most are not considered specific for psoriasis, and are related to skin inflammation or an activated epidermis in general. Therefore, a more comprehensive analysis including more specific markers for psoriasiform inflammation would be preferable. It would be also ideal to compare these findings with data on these markers in human psoriasis, and comparing GPP vs. PV. This would allow the discrimination of the model phenotype and specification of the model being a true GPP or PV model. For example, RNAseq analysis would allow for such a comparison given the publicly available RNAseq data sets from psoriasis, atopic dermatitis and other inflammatory skin conditions.

4\) The authors assess the contribution of adaptive immunity to the phenotypes described by crossing *Card14* mutants to Rag1^-/-^ mice. As no significant differences are detected in the absence of T cells and B cells, the authors conclude that adaptive immunity was not required for acute skin inflammation. This is in keeping with the relatively short time of evaluation after the induction of expression of the mutant *Card14* (5 days). Is adaptive immunity relevant at later stages of the model. If so, is anti-TNF still therapeutically effective?

5\) The study included the analysis of different cytokines (Figures 1 and 2). The results raise the question as to whether ubiquitous or KC-specific expression of *Card14*^E138A^ result in a different inflammatory profile. A table listing all the cytokines tested and their outcome in both setting would be beneficial to easily compare and contrast between the two models. Along the same line, it would be ideal to include measurements on the cellular infiltrate in the KC-specific model.

6\) There are a number of experiments in which controls are missing. For example, include control *Card14*^+/+^*Rosa26*^CreERT2/+^ in Figure 3C, Figure 3---figure supplement 1B.

7\) The data in Figure 6---figure supplement 2D is relevant and would be ideal to be included in a main figure. We also suggest to include this in the main figure and replace the pictures shown in Figure 6C.

8\) The finding that systemic effects are mediated through keratinocyte-driven severe skin inflammation is highly interesting and could have clinical impact. This finding deserves to be better highlighted in the manuscript. This may also suggest that patients could benefit, early in disease progression, from local anti-inflammatory therapies specifically targeting the keratinocytes, rather than systemic biologicals.

Revisions expected in follow-up work:

1\) We recognize that a more detailed characterization of the model and its comparison with data sets on human psoriasis, GPP and PV would require significant additional experiments and can be performed as a follow up work. A discussion on how such an approach can complement the current findings to discriminate this with other disease models would be ideal.

2\) If the authors have not tested the efficacy of anti-TNF beyond the acute period, they should clarify that this would be important to be tested in follow up work.

3\) We recognize that a thorough comparative analysis on CARD14 expression between mouse and human samples would require significant additional experiments and can be performed as a follow up work. A discussion on the implications of differential expression is warranted for this report.

10.7554/eLife.56720.sa2

Author response

> Revisions for this paper:
>
> 1\) The authors have modeled a human mutation into the mouse Card14 gene. Can the authors add a comparison on the murine gene and the human ortholog in terms of their homology?

We have added a sentence at the beginning of the Results section:

"Human and mouse CARD14 proteins are highly homologous, with 77% amino acid identity overall and 80% identity in the coiled-coil region in which the *CARD14*^E138A^ mutation is located (Figure 1---figure supplement 1A)."

Additionally, we have added a human and mouse CARD14 amino acid sequence alignment in of the conserved region around the psoriasis point mutation E138 (Figure 1---figure supplement 1A).

> 2\) The authors defined the expression of CARD14 through western blot and RNAscope approaches. The results are in line with previously published murine data, as well as with single cell sequencing data from the Kaspar lab (http://kasperlab.org/mouseskin). However, the results seem to be in contrast to protein expression profiles reported in human skin, in which CARD14 protein is mostly found in basal cells (of note: Figure 1B also shows signal in basal cells). This requires a thorough analysis or at least a discussion on the differences between mice and human and potential consequences for disease mechanisms.

Two studies have suggested that human CARD14 is expressed in the basal layer of the epidermis based IHC analyses. In Jordan et al., 2012, a Sigma antibody (HPA023388) was used to stain frozen skin sections. The second study (Fuchs-Telem et al., 2012), investigating the role of CARD14 in PRP, showed basal staining apparently using a different CARD14 antibody (NBP1-88598; Novus Biological). However, this antibody actually appears to be identical to the Sigma antibody (same immunogen sequence, same host species and same staining pictures used to advertise the antibody). Both suppliers have discontinued these antibodies and no staining with these reagents are reported for CARD14 in the human protein atlas.

We have tried the Sigma CARD14 antibody ourselves for western blotting (J.M. and S.C.L.). Using lysates from HACAT cells overexpressing CARD14-FLAG, the antibody failed to detect any specific signal although the recombinant CARD14 was clearly detected with anti-FLAG. Jordan et al., 2012 performed a negative control stained with 1% serum in lieu of the primary antibody. While this controls for unspecific retention of primary antibodies by the tissue, it does not control for unspecific binding of the specific CARD14 antibody (a better control for unspecific binding would be CARD14 knock out tissue or antibody adsorption with CARD14 recombinant protein prior to staining). Fuchs-Telem et al., 2012 do not show any negative controls. We are concerned that the basal staining with the commercial CARD14 antibodies do not actually show CARD14 protein levels and do not feel that it is possible at this stage to make a definitive statement about differences in CARD14 expression in the skin of mice and humans.

Nevertheless, similar to mouse keratinocytes, we found that differentiation of human keratinocytes increased levels of CARD14 protein and mRNA (Figure 1---figure supplement 1E and F). This is consistent with published RNA sequencing data with cultured human keratinocytes and organotypic epidermis (Bin et al., 2016) (Lopez-Pajares et al., 2015). It will be important to determine whether CARD14 protein levels similarly increase as keratinocytes differentiate in human skin and to confirm CARD14 protein expression in the basal layer using different CARD14 antibodies with validated specificity.

We have modified the text in the Results describing CARD14 localization to take in to account these considerations:

"RNAscope analysis revealed that *Card14* mRNA expression in healthy mouse skin was restricted to the upper (most differentiated) keratinocytes, the outer root sheath of the hair and sebocytes in the skin (Figure 1B). \[...\] The *CARD14* mRNA expression data agree with published transcriptomic datasets of differentiating human keratinocytes (Bin et al., 2016) and organotypic epidermis (Lopez-Pajares et al., 2015) (Figure 1---figure supplement 1G)."

Additionally, RNAscope staining of *Card14* in the skin of *Card14^LSL-E138A/+^Rosa26^CreERT2/+^* mice 5 days after tamoxifen induction has been included (Figure 3---figure supplement 2A), with the accompanying text:

"Expression of *Card14* mRNA in the skin of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice 5d after tamoxifen injection was preferentially localized to the suprabasal layers of the epidermis (Figure 3---figure supplement 2A). \[...\] These results suggest that keratinocytes are the main source of TNF driving skin inflammation."

Importantly, the new *Tnfα* RNAscope data added indicate that TNF is mainly produced by skin keratinocytes in *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice following tamoxifen induction, consistent with CARD14^E138A^ signaling in keratinocytes driving skin inflammation.

Finally, we have now added text about CARD14 epidermal expression in the Discussion:

"Earlier immunohistochemical studies established that CARD14 protein was expressed in the basal layer in human skin (Jordan et al., 2012b). \[...\] Nevertheless, regardless of apparent differences in CARD14 distribution between mouse and human, the predominant localization of CARD14 in the skin is consistent with a function in sensing harmful stimuli, such as pathogens, at the interface between the organism and the environment."

> 3\) Throughout the manuscript, the authors link their results to \'psoriasis\' (e.g. disease markers, therapeutic response). However, the investigated CARD14 mutation is related to GPP, not (or to a lesser extent) to other psoriasis endotypes like PV (Berki et al. JID 2015). The characterization of the inflammatory response includes several markers (e.g. KI67, S100A9, cytokines and chemokines). But most are not considered specific for psoriasis, and are related to skin inflammation or an activated epidermis in general. Therefore, a more comprehensive analysis including more specific markers for psoriasiform inflammation would be preferable. It would be also ideal to compare these findings with data on these markers in human psoriasis, and comparing GPP vs. PV. This would allow the discrimination of the model phenotype and specification of the model being a true GPP or PV model. For example, RNAseq analysis would allow for such a comparison given the publicly available RNAseq data sets from psoriasis, atopic dermatitis and other inflammatory skin conditions.

To answer this important point, we have included new data (Figure 5---figure supplement 1, Figure 5---figure supplement 2 and Figure 5---figure supplement 3). The following subsection was added to the Results section to describe these figures:

"Comparison of the CARD14^E138A^ skin transcriptome with human psoriatic skin transcriptome".

We have also added a discussion of these comparisons in the Discussion section:

"The skin transcriptome of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ mice also shared similarities with the skin transcriptome of the GPP patient expressing the *CARD14*^E138A^ variant. The increased expression of *Steap1* and *Steap4* mRNAs in the skin of *Card14*^LSL-E138A/+^*Rosa26*^CreERT2^ mice after tamoxifen injection is particularly interesting since these genes have been found to be upregulated in several types of pustular psoriasis and are known to be important in neutrophil chemotaxis (Liang et al., 2017b)."

> 4\) The authors assess the contribution of adaptive immunity to the phenotypes described by crossing Card14 mutants to Rag1^-/-^ mice. As no significant differences are detected in the absence of T cells and B cells, the authors conclude that adaptive immunity was not required for acute skin inflammation. This is in keeping with the relatively short time of evaluation after the induction of expression of the mutant Card14 (5 days). Is adaptive immunity relevant at later stages of the model. If so, is anti-TNF still therapeutically effective?

To address this question, we have included new experiments which investigate the importance of the adaptive immune system for skin inflammation induced by chronic CARD14^E138A^ signaling (Figure 4---figure supplement 1).

The following text was added at the Results section to describe these new data:

"To investigate the role of the adaptive immune system in skin pathology induced by prolonged CARD14^E138A^ signaling, *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^*Rag1*^-/-^ mice were analyzed 1m after tamoxifen injection. \[...\] Thus, the adaptive immune system was not required for skin inflammation induced by chronic CARD14^E138A^ signaling."

The following text was added at the Discussion section:

"The absence of a requirement for adaptive immune cells for the development of skin inflammation in *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice contrasts with a published study by Wang et al. where the inflammatory skin phenotype in mice constitutively expressing CARD14^∆Q136^ was reduced by RAG1 deficiency. \[...\] Alternatively, the inflammatory skin phenotype that develops in C*ard14*^∆Q136/+^ mice may involve developmental alterations that occur in utero that require adaptive immune cells."

Unfortunately, we have not been able to investigate the role of TNF at later time points after tamoxifen injection due to the lockdown closure of the Crick laboratories. We plan to investigate whether anti-TNF blocks the inflammatory effects of chronic CARD14^E138A^ signaling when the Institute reopens.

> 5\) The study included the analysis of different cytokines (Figures 1 and 2). The results raise the question as to whether ubiquitous or KC-specific expression of Card14^E138A^ result in a different inflammatory profile. A table listing all the cytokines tested and their outcome in both setting would be beneficial to easily compare and contrast between the two models. Along the same line, it would be ideal to include measurements on the cellular infiltrate in the KC-specific model.

We thank the reviewers for this suggestion. Unfortunately, we have not performed an RNAseq analysis of the skins of the *Card14*^E138A/+^*Krt14*^CreERT2^ mice and only checked the expression of selected proinflammatory transcripts relevant in skin inflammation by qRT-PCR. Nevertheless, we were able to show that keratinocyte-specific expression of CARD14^E138A^ upregulated the expression of the same genes induced by ubiquitous CARD14^E138A^ expression.

We have included Figure 2---figure supplement 2 comparing the fold changes of the assessed gene products.

The following text was added in the Results section:

"Some *Card14*^E138A/+^*Krt14*^CreERT2/+^ mice presented a visible skin phenotype without tamoxifen injection, which could be due to leaky expression of Cre allowing basal expression of CARD14^E138A^, these were excluded from experiments. \[...\] Nevertheless, these experiments showed that CARD14^E138A^ signalling in keratinocytes alone was sufficient to induce skin inflammation."

And we discussed the results in the following paragraph of the Discussion section:

"The fold changes of the majority of proinflammatory genes analyzed at d5 in *Card14*^LSL-E138A/+^*Krt14*^CreERT2/+^ with respect to controls were lower than the fold changes of the *Card14*^LSL-E138A/+^*Rosa26*^CreERT2/+^ mice. \[...\] Regardless, the induced genes were the same in both Cre drivers and the phenotype of both het and hom mice in the *Krt14*^CreERT2/+^ background was similar to the *Rosa26*^CreERT2/+^ histologically and systemically demonstrating that CARD14^E138A^ signaling in keratinocytes alone is sufficient to induce skin and systemic inflammation."

Unfortunately, we have not been able to perform experiments to characterize the immune cell infiltrate in the *Card14*^LSL-E138A/+^*Krt14*^CreERT2/+^ background due to closure of the Crick laboratories during the pandemic.

> 6\) There are a number of experiments in which controls are missing. For example, include control Card14^+/+^ Rosa26^CreERT2/+^ in Figure 3C, Figure 3---figure supplement 1B.

We thank the reviewers for pointing out this omission. We have now included controls in all the figure panels.

> 7\) The data in Figure 6---figure supplement 2D is relevant and would be ideal to be included in a main figure. We also suggest to include this in the main figure and replace the pictures shown in Figure 6C.

We have moved the data as suggested.

> 8\) The finding that systemic effects are mediated through keratinocyte-driven severe skin inflammation is highly interesting and could have clinical impact. This finding deserves to be better highlighted in the manuscript. This may also suggest that patients could benefit, early in disease progression, from local anti-inflammatory therapies specifically targeting the keratinocytes, rather than systemic biologicals.

We thank the reviewers for point out this important point. We have now modified the text to highlight the potential translational impact of our study:

Abstract:

"These results suggest that anti-inflammatory therapies specifically targeting keratinocytes, rather than systemic biologicals, might be effective for GPP treatment early in disease progression."

Introduction:

"This severe systemic phenotype resulted from CARD14^E138A^ signaling in keratinocytes and showed striking similarities to an acute flare of GPP in human patients. \[...\] Our findings suggest that specific blockade of the CARD14 signaling pathway in keratinocytes would inhibit the systemic inflammatory syndrome that can develop in GPP patients with activating CARD14 mutations"

Discussion:

"The present study indicates that constitutive CARD14^E138A^ activation of NF-кB in keratinocytes is sufficient to promote skin inflammation and systemic inflammatory disease. This raises the possibility that it may be feasible to develop topical medicines that block CARD14 signaling in the skin to treat CARD14-induced psoriasis and systemic inflammation."

> Revisions expected in follow-up work:
>
> 1\) We recognize that a more detailed characterization of the model and its comparison with data sets on human psoriasis, GPP and PV would require significant additional experiments and can be performed as a follow up work. A discussion on how such an approach can complement the current findings to discriminate this with other disease models would be ideal.

We have been able to address this point with new bioinformatic analyses, comparing human skin disease and mouse transcriptomics. The results are included in the article in Figure 5---figure supplements 1, 2 and 3 and described in the subsection "Comparison of the CARD14^E138A^ skin transcriptome with human psoriatic skin transcriptome".

> 2\) If the authors have not tested the efficacy of anti-TNF beyond the acute period, they should clarify that this would be important to be tested in follow up work.

We have not been able to investigate the effect of anti-TNF on skin inflammation induced by chronic CARD14^E138A^ signaling due to the coronavirus pandemic. However, we plan to perform experiments to address this question in the future. As suggested by reviewers, we have included the following text:

"It will be important to test whether anti-TNF treatment can prevent chronic skin inflammation induced by CARD14^E138A^."

> 3\) We recognize that a thorough comparative analysis on CARD14 expression between mouse and human samples would require significant additional experiments and can be performed as a follow up work. A discussion on the implications of differential expression is warranted for this report.

We have analysed publicly available RNAseq datasets from human keratinocytes and organotypic cultures under differentiation conditions (Figure 1---figure supplement 1G). These analyses have shown that *CARD14* mRNA levels increase during human keratinocyte differentiation. We have tested several commercial antibodies against CARD14 in human skin but all of these only produced nonspecific staining. Development of better CARD14 antibodies is required to definitively determine where CARD14 is expressed in the human epidermis.

We have introduced a paragraph in the Discussion in response to the reviewers' suggestion:

**"**Earlier immunohistochemical studies established that CARD14 protein is expressed in the basal layer in human skin (Jordan et al., 2012b). \[...\] Nevertheless, regardless of apparent differences in CARD14 distribution between mouse and human, the predominant localization of CARD14 in the skin is consistent with a function in sensing harmful stimuli, such as pathogens, at the interface between the organism and the environment."

[^1]: These authors contributed equally to this work.
